

# A living WHO guideline on drugs for covid-19

BMJ, The

370, m3379

DOI: [10.1136/bmj.m3379](https://doi.org/10.1136/bmj.m3379)

Citation Report

#	ARTICLE	IF	CITATIONS
1	SARS-CoV-2 virus infection: Targets and antiviral pharmacological strategies. Journal of Evidence-Based Medicine, 2020, 13, 255-260.	1.8	30
2	Clinical management of lung cancer patients during the outbreak of COVID-19 epidemic. Infectious Agents and Cancer, 2020, 15, 56.	2.6	5
3	Early management of critically ill patients with COVID-19. Journal of the American College of Emergency Physicians Open, 2020, 1, 1418-1426.	0.7	2
4	The ten reasons why corticosteroid therapy reduces mortality in severe COVID-19. Intensive Care Medicine, 2020, 46, 2067-2070.	8.2	38
5	Increasing Age, the Existence of Comorbidities, and Corticosteroid Treatment in Combination With Antiviral Therapy Prolongs the Recovery of SARS-COV-2-Infected Patients, Measured as the Conversion From Positive to Negative rtPCR: A 239 Patients' Retrospective Study. Frontiers in Medicine, 2020, 7, 575439.	2.6	2
6	Covid -19, misinformation, and antimicrobial resistance. BMJ, The, 2020, 371, m4501.	6.0	22
7	Recommendations for the Diagnosis, Prevention, and Control of Coronavirus Disease-19 in Children—The Chinese Perspectives. Frontiers in Pediatrics, 2020, 8, 553394.	1.9	26
8	Management of Pediatric Kidney Transplant Patients During the COVID-19 Pandemic: Guidance From the Canadian Society of Transplantation Pediatric Group. Canadian Journal of Kidney Health and Disease, 2020, 7, 205435812096784.	1.1	17
9	Efficacy and Safety of Lopinavir/Ritonavir for Treatment of COVID-19: A Systematic Review and Meta-Analysis. Tropical Medicine and Infectious Disease, 2020, 5, 180.	2.3	34
10	Remdesivir: a pendulum in a pandemic. BMJ, The, 2020, 371, m4560.	6.0	4
11	Covid-19: The lost lessons of Tamiflu. BMJ, The, 2020, , m4701.	6.0	5
12	Developing Guidelines Before, During, and After the COVID-19 Pandemic. Annals of Internal Medicine, 2020, 173, 1012-1014.	3.9	18
13	Drug treatments for covid-19: living systematic review and network meta-analysis. BMJ, The, 2020, 370, m2980.	6.0	592
14	Producing and using timely comparative evidence on drugs: lessons from clinical trials for covid-19. BMJ, The, 2020, 371, m3869.	6.0	16
15	Dexamethasone in hospitalised patients with COVID-19: addressing uncertainties. Lancet Respiratory Medicine, the, 2020, 8, 1170-1172.	10.7	98
16	Covid-19: We need to understand the risks to tackle them. BMJ, The, 2020, , m3790.	6.0	1
17	Can Natural Polyphenols Help in Reducing Cytokine Storm in COVID-19 Patients?. Molecules, 2020, 25, 5888.	3.8	25
18	Predicting outcomes in COVID-19: From internal validation to improving care. EBioMedicine, 2020, 61, 103090.	6.1	0

#	ARTICLE	IF	CITATIONS
19	Covid-19: EU countries spent over â‚¬220m stockpiling remdesivir despite lack of effectiveness, finds investigation. BMJ, The, 2020, 371, m4749.	6.0	3
20	Pharmacological principles guiding prolonged glucocorticoid treatment in ARDS. Intensive Care Medicine, 2020, 46, 2284-2296.	8.2	79
21	Sepsis in the critically ill patient: current and emerging management strategies. Expert Review of Anti-Infective Therapy, 2021, 19, 635-647.	4.4	12
22	Dexamethasone in Hospitalized Patients with Covid-19. New England Journal of Medicine, 2021, 384, 693-704.	27.0	8,063
23	Weekly updates of national living evidence-based guidelines: methods for the Australian living guidelines for care of people with COVID-19. Journal of Clinical Epidemiology, 2021, 131, 11-21.	5.0	50
24	Corticosteroids for Patients With Coronavirus Disease 2019 (COVID-19) With Different Disease Severity: A Meta-Analysis of Randomized Clinical Trials. Journal of Cardiothoracic and Vascular Anesthesia, 2021, 35, 578-584.	1.3	73
25	SARS-CoV-2: Targeted managements and vaccine development. Cytokine and Growth Factor Reviews, 2021, 58, 16-29.	7.2	44
26	Anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen therapy: Results of a prospective, open-label, interventional study. International Journal of Infectious Diseases, 2021, 103, 288-296.	3.3	66
27	COVID-19 vaccines: one step towards the beginning of the end of the global impact of the pandemic. Anaesthesia, 2021, 76, 435-443.	3.8	4
28	Integrating research into clinical practice: challenges and solutions for Canada. Cmaj, 2021, 193, E127-E131.	2.0	24
29	Severe COVID-19 Infectionsâ€™ Knowledge Gained and Remaining Questions. JAMA Internal Medicine, 2021, 181, 9.	5.1	15
30	Acyclovir As a Potential Add-On Treatment for COVID-19; A Narrative Review. SSRN Electronic Journal, 0, , .	0.4	1
32	COVID-19 and Sepsis. Turkish Journal of Medical Sciences, 2021, 51, 3301-3311.	0.9	37
33	Viral infections in lung transplantation. Journal of Thoracic Disease, 2021, 13, 6673-6694.	1.4	9
34	SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. The Cochrane Library, 0, , .	2.8	16
35	The emergence of post-COVID-19 mucormycosis in India: Can we prevent it?. Indian Journal of Ophthalmology, 2021, 69, 1645.	1.1	21
36	Secondary organizing pneumonia after coronavirus disease 2019: Two cases. Respiratory Medicine Case Reports, 2021, 32, 101356.	0.4	12
37	Severe warm autoimmune hemolytic anemia in COVID-19 managed with least incompatible RBC product and glucocorticoids. Annals of Hematology, 2022, 101, 431-432.	1.8	6

#	ARTICLE	IF	CITATIONS
38	Macrophage Migration Inhibitory Factor (MIF) Plasma Concentration in Critically Ill COVID-19 Patients: A Prospective Observational Study. <i>Diagnostics</i> , 2021, 11, 332.	2.6	19
39	Association between convalescent plasma and the risk of mortality among patients with COVID-19: a meta-analysis. <i>F1000Research</i> , 2021, 10, 64.	1.6	5
40	Remdesivir for COVID-19 in Europe: will it provide value for money?. <i>Lancet Respiratory Medicine</i> , the, 2021, 9, 127-128.	10.7	14
41	Drug Repurposing in the COVID-19 Era: Insights from Case Studies Showing Pharmaceutical Peculiarities. <i>Pharmaceutics</i> , 2021, 13, 302.	4.5	24
42	Case Discussion and Literature Review: Cancer Immunotherapy, Severe Immune-Related Adverse Events, Multi-Inflammatory Syndrome, and Severe Acute Respiratory Syndrome Coronavirus 2. <i>Frontiers in Oncology</i> , 2021, 11, 625707.	2.8	7
44	Efficacy and safety outcomes with remdesivir in COVID-19 patients: A meta-analysis. <i>World Journal of Meta-analysis</i> , 2021, 9, 74-87.	0.1	1
45	Higher vs Lower Doses of Dexamethasone in Patients with COVID-19 and Severe Hypoxia (COVID STEROID) Tj ETQq0 0 0 rgBT /Overlo 702-710.	1.6	13
46	Pharmacological considerations for the treatment of COVID-19 in people living with HIV (PLWH). <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1127-1141.	1.8	9
47	Efficacy and safety of systematic corticosteroids among severe COVID-19 patients: a systematic review and meta-analysis of randomized controlled trials. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 83.	17.1	57
49	COVID-19: Rethinking the Lockdown Groupthink. <i>Frontiers in Public Health</i> , 2021, 9, 625778.	2.7	80
50	Gestione del Covid-19 in et� pediatrica: documento di consenso. <i>Medico E Bambino</i> , 2021, 40, 85-101.	0.1	5
51	Balancing Healthcare and Economy Amidst the COVID-19 Pandemic: An Indian Experience. <i>Risk Management and Healthcare Policy</i> , 2021, Volume 14, 827-833.	2.5	6
53	Expert consensus statements for the management of COVID-19-related acute respiratory failure using a Delphi method. <i>Critical Care</i> , 2021, 25, 106.	5.8	121
54	Remdesivir. <i>Hospital Pharmacy</i> , 2023, 58, 420-430.	1.0	3
55	Are nucleotide inhibitors, already used for treating hepatitis C virus infection, a potential option for the treatment of COVID-19 compared with standard of care? A literature review. <i>World Journal of Virology</i> , 2021, 10, 53-61.	2.9	0
56	Tocilizumab administration in COVID-19 patients: Water on the fire or gasoline?. <i>Medical Mycology Case Reports</i> , 2021, 31, 32-34.	1.3	14
57	Association between convalescent plasma and the risk of mortality among patients with COVID-19: a meta-analysis. <i>F1000Research</i> , 0, 10, 64.	1.6	2
59	Skeletal Muscle Wasting and Function Impairment in Intensive Care Patients With Severe COVID-19. <i>Frontiers in Physiology</i> , 2021, 12, 640973.	2.8	58

#	ARTICLE	IF	CITATIONS
60	Real-life use of remdesivir in hospitalized patients with COVID-19. <i>Revista Espanola De Quimioterapia</i> , 2021, 34, 136-140.	1.3	20
61	SARS-CoV-2 and pediatric solid organ transplantation: Current knowns and unknowns. <i>Pediatric Transplantation</i> , 2021, 25, e13986.	1.0	6
62	A living WHO guideline on drugs to prevent covid-19. <i>BMJ, The</i> , 2021, 372, n526.	6.0	73
64	Impact of pathogen reduction methods on immunological properties of the COVID-19 convalescent plasma. <i>Vox Sanguinis</i> , 2021, 116, 665-672.	1.5	13
65	Cytopathology of bronchoalveolar lavages in COVID-19 pneumonia: A pilot study. <i>Cancer Cytopathology</i> , 2021, 129, 632-641.	2.4	10
67	COVID-19 in Children: Respiratory Involvement and Some Differences With the Adults. <i>Frontiers in Pediatrics</i> , 2021, 9, 622240.	1.9	15
68	A Community-Based Model to the COVID-19 Humanitarian Crisis. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 639579.	3.9	8
70	<scp>COVID</scp>-19: immunopathology, pathophysiological mechanisms, and treatment options. <i>Journal of Pathology</i> , 2021, 254, 307-331.	4.5	86
71	Therapeutic strategies for severe COVID-19: a position paper from the Italian Society of Infectious and Tropical Diseases (SIMIT). <i>Clinical Microbiology and Infection</i> , 2021, 27, 389-395.	6.0	37
72	Second wave of the COVID-19 pandemic: D-dimer levels are not so high anymore. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 52, 779-781.	2.1	1
73	Absence of "Cytokine Storm" in Hospitalized COVID-19 Patients: A Retrospective Cohort Study. <i>Infectious Disease Reports</i> , 2021, 13, 377-387.	3.1	3
74	Epidemiological and clinical characteristics of 65 hospitalized patients with COVID-19 in Liaoning, China. <i>World Journal of Clinical Cases</i> , 2021, 9, 2205-2217.	0.8	3
75	Prophylaxis against covid-19: living systematic review and network meta-analysis. <i>BMJ, The</i> , 2021, 373, n949.	6.0	78
76	Guidelines should not pool evidence from uncomplicated and severe COVID-19. <i>Lancet, The</i> , 2021, 397, 1262-1263.	13.7	11
77	Clinical management of patients with rheumatoid arthritis during the COVID-19 pandemic. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 561-571.	3.0	10
79	Acceptance and attitudes toward COVID-19 vaccines: A cross-sectional study from Jordan. <i>PLoS ONE</i> , 2021, 16, e0250555.	2.5	304
80	Ivermectin for preventing and treating COVID-19. <i>The Cochrane Library</i> , 0, , .	2.8	25
81	Remdesivir for treatment of COVID-19; an updated systematic review and meta-analysis. <i>European Journal of Pharmacology</i> , 2021, 897, 173926.	3.5	82

#	ARTICLE	IF	CITATIONS
82	IL-6 modulation for COVID-19: the right patients at the right time?. , 2021, 9, e002285.		32
83	Quality and consistency of clinical practice guidelines for treating children with COVID-19. Annals of Translational Medicine, 2021, 9, 633-633.	1.7	9
84	Corticosteroids in COVID-19 and non-COVID-19 ARDS: a systematic review and meta-analysis. Intensive Care Medicine, 2021, 47, 521-537.	8.2	148
85	Attenuating the Effects of Novel COVID-19 (SARS-CoV-2) Infection-Induced Cytokine Storm and the Implications. Journal of Inflammation Research, 2021, Volume 14, 1487-1510.	3.5	50
86	We need clinical guidelines fit for a pandemic. BMJ, The, 2021, 373, n1093.	6.0	8
87	COVID-19 Management in the Pediatric Age: Consensus Document of the COVID-19 Working Group in Paediatrics of the Emilia-Romagna Region (RE-CO-Ped), Italy. International Journal of Environmental Research and Public Health, 2021, 18, 3919.	2.6	25
88	A framework for prospective, adaptive meta-analysis (FAME) of aggregate data from randomised trials. PLoS Medicine, 2021, 18, e1003629.	8.4	21
89	COVID-19: breaking down a global health crisis. Annals of Clinical Microbiology and Antimicrobials, 2021, 20, 35.	3.8	175
90	Drug repurposing of dermatologic medications to treat coronavirus disease 2019: Science or fiction?. Clinics in Dermatology, 2021, 39, 430-445.	1.6	2
91	Questioning Tocilizumab Use in Hospitalized Patients With Coronavirus Disease 2019. Chest, 2021, 159, 2115-2116.	0.8	0
92	Covid-19: Why we must temper urgency with diligence. BMJ, The, 0, , n1210.	6.0	0
93	Existing Drugs Considered as Promising in COVID-19 Therapy. International Journal of Molecular Sciences, 2021, 22, 5434.	4.1	24
94	Calcifediol Treatment and Hospital Mortality Due to COVID-19: A Cohort Study. Nutrients, 2021, 13, 1760.	4.1	71
95	Drug Repurposing for the Treatment of COVID-19: A Knowledge Graph Approach. Advanced Therapeutics, 2021, 4, 2100055.	3.2	12
96	The second wave of desaturation in coronavirus disease 2019. New Microbes and New Infections, 2021, 41, 100866.	1.6	1
97	Immunosuppression and Clostridioides (Clostridium) difficile Infection Risk in Metabolic and Bariatric Surgery Patients. Journal of the American College of Surgeons, 2021, 233, 223-231.	0.5	5
98	Insights into SARS-CoV-2 Persistence and Its Relevance. Viruses, 2021, 13, 1025.	3.3	37
99	SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19. The Cochrane Library, 0, , .	2.8	2

#	ARTICLE	IF	CITATIONS
100	Keeping a Balance During the Pandemic: a Narrative Review on the Important Role of Micronutrients in Preventing Infection and Reducing Complications of COVID-19. Current Nutrition Reports, 2021, 10, 200-210.	4.3	9
102	Use of repurposed and adjuvant drugs in hospital patients with covid-19: multinational network cohort study. BMJ, The, 2021, 373, n1038.	6.0	50
103	Vitamin D supplementation for the treatment of COVID-19: a living systematic review. The Cochrane Library, 2021, 2021, CD015043.	2.8	78
104	Cardiometabolic Therapy and Mortality in Very Old Patients With Diabetes Hospitalized due to COVID-19. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2021, 76, e102-e109.	3.6	22
105	Simulation of Remdesivir Pharmacokinetics and Its Drug Interactions. Journal of Pharmacy and Pharmaceutical Sciences, 2021, 24, 277-291.	2.1	16
107	COVID-19 chemoprevention. International Journal of Infectious Diseases, 2021, 107, 31-33.	3.3	0
108	Pericardial Diseases in COVID19: a Contemporary Review. Current Cardiology Reports, 2021, 23, 90.	2.9	40
109	The Current Status and Challenges in the Development of Vaccines and Drugs against Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-CoV-2). BioMed Research International, 2021, 2021, 1-20.	1.9	13
111	Unbiased Analysis of Temporal Changes in Immune Serum Markers in Acute COVID-19 Infection With Emphasis on Organ Failure, Anti-Viral Treatment, and Demographic Characteristics. Frontiers in Immunology, 2021, 12, 650465.	4.8	19
112	COVID-19: biologic and immunosuppressive therapy in gastroenterology and hepatology. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 705-715.	17.8	26
113	Therapeutic Effectiveness and Safety of Repurposing Drugs for the Treatment of COVID-19: Position Standing in 2021. Frontiers in Pharmacology, 2021, 12, 659577.	3.5	31
114	Association between convalescent plasma and the risk of mortality among patients with COVID-19: a meta-analysis. F1000Research, 2021, 10, 64.	1.6	7
115	Anti-fibrotic Treatment for Pulmonary Fibrosis Induced by COVID-19: A Case Presentation. Turkish Journal of Anaesthesiology and Reanimation, 2022, 50, 228-231.	0.4	2
117	Cardiac Events Potentially Associated to Remdesivir: An Analysis from the European Spontaneous Adverse Event Reporting System. Pharmaceuticals, 2021, 14, 611.	3.8	28
118	Urgent needs to accelerate the race for COVID-19 therapeutics. EClinicalMedicine, 2021, 36, 100911.	7.1	7
119	SARS-CoV-2 RNAemia and proteomic trajectories inform prognostication in COVID-19 patients admitted to intensive care. Nature Communications, 2021, 12, 3406.	12.8	122
120	Glucocorticoid-Glucocorticoid Receptor Response to Severe Acute Respiratory Syndrome Coronavirus 2. Critical Care Medicine, 2021, Publish Ahead of Print, 2157-2160.	0.9	1
121	Drug-induced liver injury associated with lopinavir-ritonavir in patients with COVID-19: a disproportionality analysis of U.S. food and drug administration adverse event reporting system (FAERS) data. International Journal of Clinical Pharmacy, 2021, 43, 1116-1122.	2.1	10

#	ARTICLE	IF	CITATIONS
122	Therapeutic antibodies under development for SARS-CoV-2. View, 2021, , 20200178.	5.3	4
124	Cellular Uptake and Intracellular Phosphorylation of GS-441524: Implications for Its Effectiveness against COVID-19. Viruses, 2021, 13, 1369.	3.3	12
125	Acute Fulminant Mucormycosis Triggered by Covid 19 Infection in a Young Patient. Indian Journal of Otolaryngology and Head and Neck Surgery, 2022, 74, 3442-3446.	0.9	14
128	Potential impact of intervention strategies on COVID-19 transmission in Malawi: a mathematical modelling study. BMJ Open, 2021, 11, e045196.	1.9	8
129	Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia. New England Journal of Medicine, 2021, 385, 406-415.	27.0	342
130	Acyclovir as a Potential Adjuvant Therapy in COVID-19 Treatment Regimens. Pharmaceutical Sciences, 2021, , .	0.2	6
131	Ivermectin for preventing and treating COVID-19. The Cochrane Library, 2021, 2021, CD015017.	2.8	101
132	The Second Wave of COVID-19: Clinical Pharmacy Services During a Field Hospital Operation. Hospital Pharmacy, 2022, 57, 205-210.	1.0	2
133	Contemporary narrative review of treatment options for COVID-19. Respiriology, 2021, 26, 745-767.	2.3	12
134	Impacts of diabetes mellitus on clinical and para-clinical parameters among COVID-19 patients. Journal of Diabetes and Metabolic Disorders, 2021, , 1-9.	1.9	1
135	Covid-19: The UK's political gamble that bodes ill for health and the health service. BMJ, The, 0, , n1848.	6.0	4
137	Choosing Wisely for COVID-19: ten evidence-based recommendations for patients and physicians. Nature Medicine, 2021, 27, 1324-1327.	30.7	12
138	Cold agglutinin disease and COVID-19 requiring therapeutic plasma exchange. BMJ Case Reports, 2021, 14, e244227.	0.5	4
139	A cost of illness study of COVID-19 patients and retrospective modelling of potential cost savings when administering remdesivir during the pandemic "first wave" in a German tertiary care hospital. Infection, 2022, 50, 191-201.	4.7	8
141	Intravenous methylprednisolone with or without tocilizumab in patients with severe COVID-19 pneumonia requiring oxygen support: A prospective comparison. Journal of Infection and Public Health, 2021, 14, 985-989.	4.1	25
142	The Evolution of Clinical Knowledge During COVID-19: Towards a Global Learning Health System. Yearbook of Medical Informatics, 2021, 30, 176-184.	1.0	7
143	COVID-19 among patients with hematological malignancies: a national Israeli retrospective analysis with special emphasis on treatment and outcome. Leukemia and Lymphoma, 2021, 62, 3384-3393.	1.3	25
144	Theory and reality of antivirals against SARS-CoV-2. World Journal of Clinical Cases, 2021, 9, 6663-6673.	0.8	1



#	ARTICLE	IF	CITATIONS
145	Tailoring glucocorticoids in patients with severe COVID-19: a narrative review. <i>Annals of Translational Medicine</i> , 2021, 9, 1261-1261.	1.7	3
146	Caution When Comparing the Impact of Corticosteroids in COVID-19. <i>Chest</i> , 2021, 160, e243-e244.	0.8	1
147	Interventions for palliative symptom control in COVID-19 patients. <i>The Cochrane Library</i> , 2021, 2021, CD015061.	2.8	8
148	Current COVID-19 vaccine trials in high-income countries: are placebo-controlled trials ethical?. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1565-1567.	6.0	11
149	An Overview of the Pathogenesis, Transmission, Diagnosis, and Management of Endemic Human Coronaviruses: A Reflection on the Past and Present Episodes and Possible Future Outbreaks. <i>Pathogens</i> , 2021, 10, 1108.	2.8	14
150	A metaresearch study revealed susceptibility of Covid-19 treatment research to white hat bias: first, do no harm. <i>Journal of Clinical Epidemiology</i> , 2021, 136, 55-63.	5.0	9
151	Surveillance and care for confirmed and suspected patients with COVID-19 in general practice (CovidCare): study protocol for an observational trial. <i>BMC Family Practice</i> , 2021, 22, 173.	2.9	2
152	Cardiovascular disease and COVID-19: a consensus paper from the ESC Working Group on Coronary Pathophysiology & Microcirculation, ESC Working Group on Thrombosis and the Association for Acute CardioVascular Care (ACVC), in collaboration with the European Heart Rhythm Association (EHRA). <i>Cardiovascular Research</i> , 2021, 117, 2705-2729.	3.8	95
153	SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. <i>The Cochrane Library</i> , 2021, 2021, CD013825.	2.8	114
155	Mechanistic Insights into the Inhibition of SARS-CoV-2 Main Protease by Clovamide and Its Derivatives: In Silico Studies. <i>Biophysica</i> , 2021, 1, 377-404.	1.4	6
156	Severe COVID-19 in Uganda across Two Epidemic Phases: A Prospective Cohort Study. <i>American Journal of Tropical Medicine and Hygiene</i> , 2021, 105, 740-744.	1.4	10
157	Mortality Variations of COVID-19 from Different Hospital Settings During Different Pandemic Phases: A Multicenter Retrospective Study. <i>Western Journal of Emergency Medicine</i> , 2021, 22, 1051-1059.	1.1	1
158	Renal and Hepatic Toxicity Analysis of Remdesivir Formulations: Does What Is on the Inside Really Count?. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0104521.	3.2	6
159	Management of acute kidney injury associated with Covid-19. <i>Current Opinion in Nephrology and Hypertension</i> , 2021, Publish Ahead of Print, 563-570.	2.0	3
160	Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis. <i>BMJ, The</i> , 2021, 374, n2231.	6.0	59
161	Emergency drug use in a pandemic: Harsh lessons from COVID-19. <i>Cell</i> , 2021, 184, 5497-5500.	28.9	2
162	Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19. <i>Annals of Internal Medicine</i> , 2021, 174, 1261-1269.	3.9	84
163	Nutritional Immunity, Zinc Sufficiency, and COVID-19 Mortality in Socially Similar European Populations. <i>Frontiers in Immunology</i> , 2021, 12, 699389.	4.8	16

#	ARTICLE	IF	CITATIONS
164	Safety and Efficacy of Convalescent Plasma in COVID-19: An Overview of Systematic Reviews. <i>Diagnostics</i> , 2021, 11, 1663.	2.6	19
165	Repurposing clinically approved drugs for COVID-19 treatment targeting SARS-CoV-2 papain-like protease. <i>International Journal of Biological Macromolecules</i> , 2021, 188, 137-146.	7.5	32
166	Clinical trials in COVID-19 management & prevention: A meta-epidemiological study examining methodological quality. <i>Journal of Clinical Epidemiology</i> , 2021, 139, 68-79.	5.0	11
167	Recommendations on Inpatient Treatment of Patients With COVID-19. <i>Deutsches A&amp;#x0308;rzteblatt International</i> , 2021, 118, .	0.9	35
168	Pandemics Throughout History. <i>Frontiers in Microbiology</i> , 2020, 11, 631736.	3.5	330
169	Acute severe respiratory syndrome coronavirus-2 treatment overview for pediatrics. <i>Current Opinion in Pediatrics</i> , 2021, Publish Ahead of Print, 129-135.	2.0	3
170	Potential Interaction Between SARS-CoV-2 and Thyroid: A Review. <i>Endocrinology</i> , 2021, 162, .	2.8	77
171	Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. <i>BMJ, The</i> , 2021, 372, n84.	6.0	309
172	Making Sense of Contradictory Evidence in Coronavirus Disease 2019 Trials. <i>Clinical Infectious Diseases</i> , 2021, , .	5.8	1
173	Broad guidelines for primary care practitioners/standalone private health facilities/frontline healthcare facilities in view of COVID-19 pandemic. <i>Journal of Family Medicine and Primary Care</i> , 2021, 10, 1.	0.9	5
174	Anesthetic Management of a Child With Propionic Acidemia Complicated by Bacteremia and Severe Acute Respiratory Syndrome Coronavirus 2. <i>Journal of Medical Cases</i> , 2021, 12, 152-156.	0.7	2
175	Multidimensional Evaluation of All-Cause Mortality Risk and Survival Analysis for Hospitalized Patients with COVID-19. <i>International Journal of Medical Sciences</i> , 2021, 18, 3140-3149.	2.5	6
176	Potential SARS-CoV-2 3CLpro inhibitors from chromene, flavonoid and hydroxamic acid compound based on FRET assay, docking and pharmacophore studies. <i>Results in Chemistry</i> , 2021, 3, 100195.	2.0	15
179	Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications. <i>Infection and Drug Resistance</i> , 2020, Volume 13, 4673-4695.	2.7	43
180	Multisystem Inflammatory Syndrome in Children (MIS-C), a Post-viral Myocarditis and Systemic Vasculitisâ€”A Critical Review of Its Pathogenesis and Treatment. <i>Frontiers in Pediatrics</i> , 2020, 8, 626182.	1.9	120
181	The Current Status of Drug Repositioning and Vaccine Developments for the COVID-19 Pandemic. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9775.	4.1	40
182	COVID-19 treatment : a growing (anti)body of evidence. <i>South African General Practitioner</i> , 2020, 1, 172-174.	0.1	2
183	Pragmatic Recommendations for Therapeutics of Hospitalized COVID-19 Patients in Low- and Middle-Income Countries. <i>American Journal of Tropical Medicine and Hygiene</i> , 2020, , .	1.4	3

#	ARTICLE	IF	CITATIONS
184	Implications for clinical dental practice during the coronavirus disease pandemic: A scoping review. Journal of Prosthodontic Research, 2022, 66, 6-11.	2.8	4
185	The Saudi Critical Care Society practice guidelines on the management of COVID-19 in the ICU: Therapy section. Journal of Infection and Public Health, 2022, 15, 142-151.	4.1	10
186	The REMDACTA trial: do interleukin receptor antagonists provide additional benefit in COVID-19?. Intensive Care Medicine, 2021, 47, 1315-1318.	8.2	6
187	Clinical characteristics and outcomes of critically ill mechanically ventilated COVID-19 patients receiving interleukin-6 receptor antagonists and corticosteroid therapy: a preliminary report from a multinational registry. European Journal of Medical Research, 2021, 26, 117.	2.2	18
188	Longitudinal urinary biomarkers of immunological activation in covid-19 patients without clinically apparent kidney disease versus acute and chronic failure. Scientific Reports, 2021, 11, 19675.	3.3	5
189	Integrating Chinese and western medicine for COVID-19: A living evidence-based guideline (version 1). Journal of Evidence-Based Medicine, 2021, 14, 313-332.	1.8	21
190	Pathogenesis, Symptomatology, and Transmission of SARS-CoV-2 through Analysis of Viral Genomics and Structure. MSystems, 2021, 6, e0009521.	3.8	26
191	Effect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19. JAMA - Journal of the American Medical Association, 2021, 326, 1690.	7.4	169
192	Convalescent Plasma for Patients Hospitalized With Coronavirus Disease 2019: A Meta-Analysis With Trial Sequential Analysis of Randomized Controlled Trials. Transfusion Medicine Reviews, 2022, 36, 16-26.	2.0	11
193	Micronutrients for potential therapeutic use against COVID-19; a review. Clinical Nutrition ESPEN, 2021, 46, 9-13.	1.2	5
194	Potential interactions between antineoplastic agents and medicines used to treat Covid-19. Journal of Oncology Pharmacy Practice, 2021, , 107815522110404.	0.9	2
195	Covid-19: Fatal errors, not fatalism, created UK's public health disaster. BMJ, The, 0, , n2497.	6.0	2
196	Complications of Critical COVID-19. Chest, 2022, 161, 989-998.	0.8	14
197	Antibiotics for the treatment of COVID-19. The Cochrane Library, 2022, 2022, CD015025.	2.8	49
198	Real-Life Impact of Glucocorticoid Treatment in COVID-19 Mortality: A Multicenter Retrospective Study. Journal of Clinical Medicine, 2021, 10, 4678.	2.4	3
199	Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial. Intensive Care Medicine, 2021, 47, 1258-1270.	8.2	88
200	COVID-19 Advanced Care. Journal of Personalized Medicine, 2021, 11, 1082.	2.5	1
201	Effect of 12 mg vs 6 mg of Dexamethasone on the Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia. JAMA - Journal of the American Medical Association, 2021, 326, 1807.	7.4	174

#	ARTICLE	IF	CITATIONS
202	Moxidectin and Ivermectin Inhibit SARS-CoV-2 Replication in Vero E6 Cells but Not in Human Primary Bronchial Epithelial Cells. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, AAC0154321.	3.2	19
203	A novel device for treatment of osteonecrosis of femoral head: Feasibility and preliminary efficacy of animal study. <i>Journal of Orthopaedic Translation</i> , 2021, 31, 20-25.	3.9	7
204	SARS-CoV-2: Current trends in emerging variants, pathogenesis, immune responses, potential therapeutic, and vaccine development strategies. <i>International Immunopharmacology</i> , 2021, 101, 108232.	3.8	14
205	Prevention and Treatment of SARS-CoV2 Infection in People Living with HIV: The Need for Specific Data. <i>Infectious Diseases and Therapy</i> , 2021, , 1.	4.0	6
206	The Role of Glucocorticoids in Inflammatory Diseases. <i>Cells</i> , 2021, 10, 2921.	4.1	44
207	Efficacy and safety of tocilizumab versus standard care/placebo in patients with COVID-19; a systematic review and meta-analysis of randomized clinical trials. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 1955-1963.	2.4	22
208	Fulminant necrotising amoebic colitis after corticosteroid therapy for severe COVID-19. <i>BMJ Case Reports</i> , 2021, 14, e246110.	0.5	2
209	Expert Consensus Statements on the Use of Corticosteroids in Non-severe COVID-19. <i>Indian Journal of Critical Care Medicine</i> , 2021, 25, 1280-1285.	0.9	5
210	Update on treatment and preventive interventions against COVID-19: an overview of potential pharmacological agents and vaccines. <i>Molecular Biomedicine</i> , 2020, 1, 16.	4.4	4
211	COVID-19 Treatment at a Glance. <i>Turkish Thoracic Journal</i> , 2020, 21, 438-445.	0.6	2
212	COVID-19 in Lombardy seven months later: what we learned and modified in patients' management. <i>Minerva Anestesiologica</i> , 2020, 86, 1353-1354.	1.0	1
213	Vitamin D Endocrine System and COVID-19. <i>JBM Plus</i> , 2021, 5, e10576.	2.7	13
214	Identification and Development of Therapeutics for COVID-19. <i>MSystems</i> , 2021, 6, e0023321.	3.8	20
219	Differences in mortality in critically ill elderly patients during the second COVID-19 surge in Europe. <i>Critical Care</i> , 2021, 25, 344.	5.8	7
220	Treatment and therapeutic agents. , 2022, , 121-176.		0
221	Awareness, value and use of the Australian living guidelines for the clinical care of people with COVID-19: an impact evaluation. <i>Journal of Clinical Epidemiology</i> , 2022, 143, 11-21.	5.0	10
222	COVID-19, the Pandemic of the Century and Its Impact on Cardiovascular Diseases. <i>Cardiology Discovery</i> , 2021, 1, 233-258.	0.5	6
223	Seven days in medicine: 17-23 November 2021. <i>BMJ, The</i> , 2021, 375, n2871.	6.0	0

#	ARTICLE	IF	CITATIONS
224	The Organic Turn: Coping With Pandemic and Non-pandemic Challenges by Integrating Evidence-, Theory-, Experience-, and Context-Based Knowledge in Advising Health Policy. <i>Frontiers in Public Health</i> , 2021, 9, 727427.	2.7	12
225	Fragility Index and Fragility Quotient in Randomized Controlled Trials on Corticosteroids in ARDS Due to COVID-19 and Non-COVID-19 Etiology. <i>Journal of Clinical Medicine</i> , 2021, 10, 5287.	2.4	7
226	COVID-19 in Children. <i>Infectious Disease Clinics of North America</i> , 2022, 36, 1-14.	5.1	10
227	A Systematic Review on COVID-19 Vaccine Strategies, Their Effectiveness, and Issues. <i>Vaccines</i> , 2021, 9, 1387.	4.4	51
229	Intermediate-to-therapeutic versus prophylactic anticoagulation for coagulopathy in hospitalized COVID-19 patients: a systemic review and meta-analysis. <i>Thrombosis Journal</i> , 2021, 19, 91.	2.1	12
230	Mechanisms of COVID-19-induced kidney injury and current pharmacotherapies. <i>Inflammation Research</i> , 2022, 71, 39-56.	4.0	23
231	Ten months of temporal variation in the clinical journey of hospitalised patients with COVID-19: An observational cohort. <i>ELife</i> , 2021, 10, .	6.0	9
232	Guidelines developed under pressure. The case of the COVID-19 low-quality “rapid” guidelines and potential solutions. <i>Journal of Clinical Epidemiology</i> , 2022, 142, 194-199.	5.0	10
233	COVID-19 and Rheumatoid Arthritis Crosstalk: Emerging Association, Therapeutic Options and Challenges. <i>Cells</i> , 2021, 10, 3291.	4.1	38
234	Anakinra in COVID-19: A step closer to the cure. <i>European Journal of Internal Medicine</i> , 2022, 96, 113-114.	2.2	5
235	Dexamethasone 12Âmg versus 6Âmg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trial. <i>Intensive Care Medicine</i> , 2022, 48, 45-55.	8.2	70
236	Clinical outcomes of corticosteroids for COVID-19 patients at the National Center for Global Health and Medicine during the first wave of infections. <i>Respiratory Investigation</i> , 2021, , .	1.8	0
237	A Pro-Inflammatory Gut Microbiome Characterizes SARS-CoV-2 Infected Patients and a Reduction in the Connectivity of an Anti-Inflammatory Bacterial Network Associates With Severe COVID-19. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 747816.	3.9	51
238	Forced association of SARS-CoV-2 proteins with the yeast proteome perturb vesicle trafficking. <i>Microbial Cell</i> , 2021, 8, 280-296.	3.2	3
239	Potential kidney damage associated with the use of remdesivir for COVID-19: analysis of a pharmacovigilance database. <i>Cadernos De Saude Publica</i> , 2021, 37, e00077721.	1.0	13
240	Cytokine Storm, Corticosteroids and Interleukin-6 Receptor Antibodies in Context of Antiinflammatory Treatment in COVID-19. <i>Journal of Pharmaceutical Research International</i> , 0, , 67-75.	1.0	2
241	Impact of COVID-19 in hematopoietic stem cell transplant recipients: A systematic review and meta-analysis. <i>Transplant Infectious Disease</i> , 2022, 24, .	1.7	28
242	Outside any therapeutic trial prescription of hydroxychloroquine for hospitalized patients with covid-19 during the first wave of the pandemic: A national inquiry of prescription patterns among French hospitalists. <i>PLoS ONE</i> , 2022, 17, e0261843.	2.5	2

#	ARTICLE	IF	CITATIONS
243	Covid-19: WHO recommends baricitinib and sotrovimab to treat patients. BMJ, The, 2022, 376, o97.	6.0	19
244	Effects of the COVID-19 pandemic on head lice and scabies infestation dynamics: a population-based study in France. Clinical and Experimental Dermatology, 2022, 47, 867-872.	1.3	10
245	COVID-19 IN CHILDREN AND ADOLESCENT: CHARACTERISTICS AND SPECIFICITIES IN IMMUNOCOMPETENT AND ONCOHEMATOLOGICAL PATIENTS. Mediterranean Journal of Hematology and Infectious Diseases, 2022, 14, e2022009.	1.3	5
246	Understanding the activating mechanism of the immune system against COVID-19 by Traditional Indian Medicine: Network pharmacology approach. Advances in Protein Chemistry and Structural Biology, 2022, 129, 275-379.	2.3	7
248	Efficacy of remdesivir for hospitalized COVID-19 patients with end stage renal disease. World Journal of Critical Care Medicine, 2022, 11, 48-57.	1.8	2
249	High-dose ivermectin for early treatment of COVID-19 (COVER study): a randomised, double-blind, multicentre, phase II, dose-finding, proof-of-concept clinical trial. International Journal of Antimicrobial Agents, 2022, 59, 106516.	2.5	32
250	Defining Optimal Respiratory Support for Patients With COVID-19. JAMA - Journal of the American Medical Association, 2022, 327, 531.	7.4	7
251	Risk Factors for Therapeutic Intervention of Remdesivir in Mild to Moderate COVID-19: A Single-Center Retrospective Study of the COVID-19 Fourth Pandemic Period in Wakayama, Japan. Medicina (Lithuania), 2022, 58, 118.	2.0	3
252	The Australian living guidelines for the clinical care of people with COVID-19: What worked, what didn't and why, a mixed methods process evaluation. PLoS ONE, 2022, 17, e0261479.	2.5	11
253	Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial. Cmaj, 2022, 194, E242-E251.	2.0	103
254	Dealing with Corticosteroid and High-Dose Cyclosporine Therapy in a Pyoderma Gangrenosum Patient Contracting a COVID-19 Infection. Journal of Personalized Medicine, 2022, 12, 173.	2.5	2
256	Regdanvimab in patients with mild-to-moderate SARS-CoV-2 infection: A propensity score-matched retrospective cohort study. International Immunopharmacology, 2022, 106, 108570.	3.8	13
257	Very low levels of remdesivir resistance in SARS-COV-2 genomes after 18 months of massive usage during the COVID19 pandemic: A GISAID exploratory analysis. Antiviral Research, 2022, 198, 105247.	4.1	39
258	From hydroxychloroquine to ivermectin: how unproven "cures" can go viral. Clinical Microbiology and Infection, 2022, 28, 472-474.	6.0	9
259	Clinical update on COVID-19 for the emergency clinician: Presentation and evaluation. American Journal of Emergency Medicine, 2022, 54, 46-57.	1.6	146
260	An epidemic of iatrogenic Cushing's syndrome in anticipation in post-COVID era. Journal of Family Medicine and Primary Care, 2022, 11, 412.	0.9	3
261	Impact of corticosteroid therapy on the survival of critical COVID-19 patients admitted into an intensive care unit. Revista Española De Anestesiología Y Reanimación (English Edition), 2022, 69, 120-120.	0.1	0
262	Medical research needs a Sue Gray. BMJ, The, 0, , o274.	6.0	1



#	ARTICLE	IF	CITATIONS
263	Convalescent plasma in hospitalized patients with COVID-19 pneumonia: a case-control prospective study. <i>Rivista Italiana Della Medicina Di Laboratorio</i> , 0, , .	0.4	0
264	WHO covid-19 drugs guideline: reconsider using convalescent plasma. <i>BMJ, The</i> , 2022, 376, o295.	6.0	6
265	Community-Acquired Pneumonia in Canada During Coronavirus Disease 2019. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac043.	0.9	4
266	Re: "ESCMID COVID-19 living guidelines: drug treatment and clinical management" by Bartoletti et al. <i>Clinical Microbiology and Infection</i> , 2021, , .	6.0	3
267	In Silico Analysis of Inhibiting Papain-like Protease from SARS-CoV-2 by Using Plant-Derived Peptides. <i>International Journal of Peptide Research and Therapeutics</i> , 2022, 28, 24.	1.9	6
268	COVID-19 in Low- and Middle-Income Countries (LMICs): A Narrative Review from Prevention to Vaccination Strategy. <i>Vaccines</i> , 2021, 9, 1477.	4.4	25
271	Identifying factors contributing to increased susceptibility to COVID-19 risk: a systematic review of Mendelian randomization studies. <i>International Journal of Epidemiology</i> , 2022, 51, 1088-1105.	1.9	25
272	SARS-CoV-2 and Coronavirus Disease Mitigation: Treatment Options, Vaccinations and Variants. <i>Pathogens</i> , 2022, 11, 275.	2.8	9
273	A comprehensive review of adverse events to drugs used in COVID-19 patients: Recent clinical evidence. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13763.	3.4	5
274	Potentially effective drugs for the treatment of COVID-19 or MIS-C in children: a systematic review. <i>European Journal of Pediatrics</i> , 2022, 181, 2135-2146.	2.7	19
275	Use of tocilizumab and sarilumab alone or in combination with corticosteroids for covid-19: systematic review and network meta-analysis. , 2022, 1, e000036.		13
276	Adrenomedullin Therapy in Moderate to Severe COVID-19. <i>Biomedicines</i> , 2022, 10, 533.	3.2	8
277	Pharmacogenetics and Precision Medicine Approaches for the Improvement of COVID-19 Therapies. <i>Frontiers in Pharmacology</i> , 2022, 13, 835136.	3.5	17
278	EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1628-1639.	0.9	89
279	Herd Behavior in Medicine: Examples From COVID-19. <i>Cureus</i> , 2022, 14, e22472.	0.5	0
280	Therapeutics and COVID-19 "A living WHO guideline: Endorsement by the Scandinavian Society of Anaesthesiology and Intensive Care Medicine. <i>Acta Anaesthesiologica Scandinavica</i> , 2022, , .	1.6	3
281	What's new on the management of obstetric patients who tested positive for Covid-19?. <i>Minerva Anestesiologica</i> , 2022, , .	1.0	0
282	Evaluation of Antimicrobial Drug Use and Concurrent Infections During Hospitalization of Patients With COVID-19 in Japan. <i>JAMA Network Open</i> , 2022, 5, e220040.	5.9	2

#	ARTICLE	IF	CITATIONS
283	Review of Anti-inflammatory and Anti-viral therapeutics for hospitalized patients infected with SARS-CoV-2. Critical Care Clinics, 2022, , .	2.6	3
284	Long-term outcomes of dexamethasone 12Âmg versus 6Âmg in patients with COVID-19 and severe hypoxaemia. Intensive Care Medicine, 2022, 48, 580-589.	8.2	17
285	Pulmonary Inflammatory Response in Lethal COVID-19 Reveals Potential Therapeutic Targets and Drugs in Phases III/IV Clinical Trials. Frontiers in Pharmacology, 2022, 13, 833174.	3.5	6
286	In Response to: Corticosteroids in Non-severe COVID-19: Finding Window of Opportunity. Indian Journal of Critical Care Medicine, 2022, 26, 405-405.	0.9	0
288	Climate, pandemic, and war: an uncontrolled multicrisis of existential proportions. BMJ, The, 0, , o689.	6.0	3
289	COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes. Clinical Microbiology Reviews, 2022, 35, e0020021.	13.6	64
290	Inflammaging at the Time of COVID-19. Clinics in Geriatric Medicine, 2022, 38, 473-481.	2.6	14
291	Molnupiravirâ€™s authorisation was premature. BMJ, The, 2022, 376, o443.	6.0	25
293	Seroconversion rates among different designs of COVID-19 vaccines: a network meta-analysis of randomized controlled trials. F1000Research, 0, 11, 299.	1.6	0
294	Corticosteroids for Non-severe COVID-19: Primum Non Nocere. Indian Journal of Critical Care Medicine, 2022, 26, 403-404.	0.9	2
296	Association of high SARS-CoV-2 RNAemia with diabetes and mortality in critically ill COVID-19 patients. IScience, 2022, 25, 104075.	4.1	5
297	Fluvoxamine in Nonhospitalized Patients With Acute COVID-19 Infection and the Lack of Efficacy in Reducing Rates of Hospitalization, Mechanical Ventilation, and Mortality in Placebo-Controlled Trials: A Systematic Review and Meta-Analysis. American Journal of Therapeutics, 2022, 29, e298-e304.	0.9	9
298	Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies. Nature Medicine, 2022, 28, 1297-1302.	30.7	235
299	Adverse effects of remdesivir, hydroxychloroquine and lopinavir/ritonavir when used for COVID-19: systematic review and meta-analysis of randomised trials. BMJ Open, 2022, 12, e048502.	1.9	28
301	Guidelines and evidence-based recommendations in anaesthesia: where do we stand?. British Journal of Anaesthesia, 2022, , .	3.4	5
302	Unraveling the antiviral activity of plitidepsin against SARS-CoV-2 by subcellular and morphological analysis. Antiviral Research, 2022, 200, 105270.	4.1	14
303	Corticosteroid therapy in COVID-19 associated with in-hospital mortality in geriatric patients: a propensity matched cohort study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2022, , .	3.6	7
304	Liushen Capsules, a promising clinical candidate for COVID-19, alleviates SARS-CoV-2-induced pulmonary in vivo and inhibits the proliferation of the variant virus strains in vitro. Chinese Medicine, 2022, 17, 40.	4.0	8



#	ARTICLE	IF	CITATIONS
305	Definition, diagnosis, and management of COVID-19-associated pulmonary mucormycosis: Delphi consensus statement from the Fungal Infection Study Forum and Academy of Pulmonary Sciences, India. <i>Lancet Infectious Diseases</i> , The, 2022, 22, e240-e253.	9.1	41
306	Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes. <i>Cardiovascular Diabetology</i> , 2022, 21, 50.	6.8	8
307	Host Defence Peptides: A Potent Alternative to Combat Antimicrobial Resistance in the Era of the COVID-19 Pandemic. <i>Antibiotics</i> , 2022, 11, 475.	3.7	10
308	Clinical profile and mortality of Sars-Cov-2 infection in cancer patients across two pandemic time periods (Feb 2020–Sep 2020; Sep 2020–May 2021) in the Veneto Oncology Network: The ROVID study. <i>European Journal of Cancer</i> , 2022, 167, 81-91.	2.8	3
309	Clinical update on COVID-19 for the emergency and critical care clinician: Medical management. <i>American Journal of Emergency Medicine</i> , 2022, 56, 158-170.	1.6	13
310	Comparing efficacy and safety of tocilizumab and methylprednisolone in the treatment of patients with severe COVID-19. <i>International Immunopharmacology</i> , 2022, 107, 108689.	3.8	2
311	Mortality Predictors in Severe COVID-19 Patients from an East European Tertiary Center: A Never-Ending Challenge for a No Happy Ending Pandemic. <i>Journal of Clinical Medicine</i> , 2022, 11, 58.	2.4	15
312	The association between therapeutic plasma exchange and the risk of mortality among patients critically ill with COVID-19: a meta-analysis. <i>F1000Research</i> , 2021, 10, 1280.	1.6	4
313	Investigation of the Molecular Mechanism of Coagulopathy in Severe and Critical Patients With COVID-19. <i>Frontiers in Immunology</i> , 2021, 12, 762782.	4.8	4
314	High Fasting Blood Glucose Level With Unknown Prior History of Diabetes Is Associated With High Risk of Severe Adverse COVID-19 Outcome. <i>Frontiers in Endocrinology</i> , 2021, 12, 791476.	3.5	9
315	The European clinical research response to optimise treatment of patients with COVID-19: lessons learned, future perspective, and recommendations. <i>Lancet Infectious Diseases</i> , The, 2022, 22, e153-e158.	9.1	22
316	Ribavirin Treatment for Critically Ill COVID-19 Patients: An Observational Study. <i>Infection and Drug Resistance</i> , 2021, Volume 14, 5287-5291.	2.7	9
317	Antirheumatic Drugs against COVID-19 from the Perspective of Rheumatologists. <i>Pharmaceuticals</i> , 2021, 14, 1256.	3.8	10
318	Adherence of Clinical Practice Guidelines for Pharmacologic Treatments of Hospitalized Patients With COVID-19 to Trustworthy Standards. <i>JAMA Network Open</i> , 2021, 4, e2136263.	5.9	5
319	Differences in mortality in critically ill elderly patients during the second COVID-19 surge in Europe. <i>Critical Care</i> , 2021, 25, 344.	5.8	21
320	Computational prediction of the molecular mechanism of statin group of drugs against SARS-CoV-2 pathogenesis. <i>Scientific Reports</i> , 2022, 12, 6241.	3.3	12
321	The Fungal Gut Microbiome Exhibits Reduced Diversity and Increased Relative Abundance of Ascomycota in Severe COVID-19 Illness and Distinct Interconnected Communities in SARS-CoV-2 Positive Patients. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022, 12, 848650.	3.9	9
322	The Global Impact of COVID-19 on Solid Organ Transplantation: Two Years Into a Pandemic. <i>Transplantation</i> , 2022, 106, 1312-1329.	1.0	44

#	ARTICLE	IF	CITATIONS
323	Early post-infection treatment of SARS-CoV-2 infected macaques with human convalescent plasma with high neutralizing activity had no antiviral effects but moderately reduced lung inflammation. PLoS Pathogens, 2022, 18, e1009925.	4.7	8
324	Timing of Initiation of Methylprednisolone Pulse Therapy in Patients with COVID-19. Covid, 2022, 2, 532-539.	1.5	0
325	JAK inhibitors and COVID-19. , 2022, 10, e002838.		34
326	A Systematic Review Assessing the Underrepresentation of Cancer Patients in COVID-19 Trials. Acta Haematologica, 2022, 145, 235-243.	1.4	1
327	Usage of compromised lung volume in monitoring steroid therapy on severe COVID-19. Respiratory Research, 2022, 23, 105.	3.6	1
328	Emerging Therapies for COVID-19: The Value of Information From More Clinical Trials. Value in Health, 2022, , .	0.3	5
329	Heart Failure Relapses in Response to Acute Stresses “ Role of Immunological and Inflammatory Pathways. Frontiers in Cardiovascular Medicine, 2022, 9, 809935.	2.4	3
330	Metabolomic Profiling of Plasma Reveals Differential Disease Severity Markers in COVID-19 Patients. Frontiers in Microbiology, 2022, 13, 844283.	3.5	15
331	SARS-CoV-2 infection in chronic kidney disease patients with pre-existing dialysis: description across different pandemic intervals and effect on disease course (mortality). Infection, 2023, 51, 71-81.	4.7	1
332	Patients with severe COVID-19 do not have elevated autoantibodies against common diagnostic autoantigens. Clinical Chemistry and Laboratory Medicine, 2022, 60, 1116-1123.	2.3	3
333	Etiotropic therapy of the new coronavirus infection: expectations and realities at the beginning of 2022. Part 1. Russian Family Doctor, 2022, 26, 7-14.	0.1	0
334	Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9). Leukemia, 2022, 36, 1467-1480.	7.2	63
335	Steroid therapy and antiviral treatment in SARSCoV-2 pneumonia: clinical contexts and indications. Revista Espanola De Quimioterapia, 2022, 35, 54-58.	1.3	1
336	HDAC Inhibition as Potential Therapeutic Strategy to Restore the Deregulated Immune Response in Severe COVID-19. Frontiers in Immunology, 2022, 13, 841716.	4.8	15
337	An anti-SARS-CoV-2 metabolite is reduced in diabetes. Nature Metabolism, 2022, 4, 501-502.	11.9	1
338	Checking for update“living systematic reviews and clinical practice guidelines in the <i>BJD</i>. British Journal of Dermatology, 2022, 186, 761-762.	1.5	1
339	Outpatient treatment options to address the SARS-CoV-2 variant Omicron. Expert Review of Anti-Infective Therapy, 2022, 20, 1129-1133.	4.4	8
340	Epidemiology of COVID-19 in Tehran, Iran: A Cohort Study of Clinical Profile, Risk Factors, and Outcomes. BioMed Research International, 2022, 2022, 1-17.	1.9	10

#	ARTICLE	IF	CITATIONS
341	Efficacy of Colchicine in the Treatment of COVID-19 Patients: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 2022, 11, 2615.	2.4	14
342	Covid-19: Stockpiling antivirals risks repeating Tamiflu mistakes, experts warn. BMJ, The, 2022, 377, o1053.	6.0	1
343	Immune-based Therapeutic Approaches in COVID-19. Biomedicine and Pharmacotherapy, 2022, , 113107.	5.6	4
344	Molnupiravir might be dangerous without clarification of its indications. BMJ, The, 2022, 377, o1030.	6.0	5
345	Remd��sivir chez les patients hospitalis��s pour la COVID-19 au Canada: essai clinique randomis�� et contr��l��. Cmaj, 2022, 194, E713-E723.	2.0	0
346	Management of Hematologic Malignancies in the Era of COVID-19 Pandemic: Pathogenetic Mechanisms, Impact of Obesity, Perspectives, and Challenges. Cancers, 2022, 14, 2494.	3.7	7
347	Challenges in addressing inequity in access to COVID-19 diagnostics, therapeutics and vaccines in Africa. South African Journal of Science, 2022, 118, .	0.7	1
349	Corticosteroids and superinfections in COVID-19 patients on invasive mechanical ventilation. Journal of Infection, 2022, 85, 57-63.	3.3	29
350	Mortality in SARS-CoV-2 Hospitalized Patients Treated with Remdesivir: A Nationwide, Registry-Based Study in Italy. Viruses, 2022, 14, 1197.	3.3	8
351	Remdesivir for the treatment of COVID-19: a systematic review and meta-analysis. Clinical Microbiology and Infection, 2022, 28, 1203-1210.	6.0	50
352	Prognostic Factors Associated With Mortality of Patients With COVID-19 Requiring Ventilator Management: A Retrospective Cohort Study. Cureus, 2022, , .	0.5	1
353	Evolving outcomes of extracorporeal membrane oxygenation during the first 2��years of the COVID-19 pandemic: a systematic review and meta-analysis. Critical Care, 2022, 26, .	5.8	34
354	Construct Validity and Responsiveness of the COVID-19 Yorkshire Rehabilitation Scale (C19-YRS) in a Cohort of Italian Hospitalized COVID-19 Patients. International Journal of Environmental Research and Public Health, 2022, 19, 6696.	2.6	11
355	Covid-19, an unfinished story. Presse Medicale, 2022, 51, 104131.	1.9	8
356	Baricitinib as the treatment of choice for hospitalised individuals with COVID-19. EclinicalMedicine, 2022, 49, 101493.	7.1	5
357	SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19. The Cochrane Library, 2022, 2022, .	2.8	20
358	How frequently should â��living�� guidelines be updated? Insights from the Australian Living Stroke Guidelines. Health Research Policy and Systems, 2022, 20, .	2.8	5
359	The AI-Assisted Identification and Clinical Efficacy of Baricitinib in the Treatment of COVID-19. Vaccines, 2022, 10, 951.	4.4	8

#	ARTICLE	IF	CITATIONS
360	Parenteral Vitamin C in Patients with Severe Infection: A Systematic Review. , 2022, 1, .		20
361	Remdesivir for the treatment of patients hospitalized with COVID-19 receiving supplemental oxygen: a targeted literature review and meta-analysis. Scientific Reports, 2022, 12, .	3.3	21
362	Real-life use of remdesivir-containing regimens in COVID-19: a retrospective case-control study. Infezioni in Medicina, 2022, 30, .	1.1	5
363	Chasing the Ghost: Hyperinflammation Does Not Cause Sepsis. Frontiers in Pharmacology, 0, 13, .	3.5	3
364	Changes in dispensing of medicines proposed for re-purposing in the first year of the COVID-19 pandemic in Australia. PLoS ONE, 2022, 17, e0269482.	2.5	5
365	Janus kinase inhibitors for the treatment of COVID-19. The Cochrane Library, 2022, 2022, .	2.8	22
366	The role of natural products from medicinal plants against COVID-19: traditional medicine practice in Tanzania. Heliyon, 2022, 8, e09739.	3.2	9
367	Ivermectin for preventing and treating COVID-19. The Cochrane Library, 2024, 2024, .	2.8	19
368	Long-COVID in children and adolescents: a systematic review and meta-analyses. Scientific Reports, 2022, 12, .	3.3	203
369	A Multi-Center, Open-Label, Randomized Controlled Trial to Evaluate the Efficacy of Convalescent Plasma Therapy for Coronavirus Disease 2019: A Trial Protocol (COVIPLA-RCT). Life, 2022, 12, 856.	2.4	4
370	COVID-19, haemophagocytic lymphohistiocytosis, and infection-induced cytokine storm syndromes. Lancet Infectious Diseases, The, 2022, 22, 937-938.	9.1	4
371	Clinical Characteristics of COVID-19: Use of Steroids in Mostly Unvaccinated COVID-19 Patients Before the Omicron Variant. Journal of Korean Medical Science, 2022, 37, .	2.5	3
372	Apprising the need for a living guideline approach in the COVID-19 era. Journal of Anaesthesiology Clinical Pharmacology, 2022, 38, 143.	0.7	0
373	Immunomodulatory therapy in dengue: need for clinical trials and evidence base. Archives of Disease in Childhood, 0, , archdischild-2022-324100.	1.9	1
374	Perspectives on the production, and use, of rapid evidence in decision making during the COVID-19 pandemic: a qualitative study. BMJ Evidence-Based Medicine, 2023, 28, 48-57.	3.5	3
375	The Relationship between COVID-19 and Hypothalamicâ€Pituitaryâ€Adrenal Axis: A Large Spectrum from Glucocorticoid Insufficiency to Excessâ€The CAPISCO International Expert Panel. International Journal of Molecular Sciences, 2022, 23, 7326.	4.1	30
376	Participantsâ€™ informed consent in adaptive, platform drug trials in hospitalized COVID-19 patients: Not all approaches are ethically acceptable. European Journal of Internal Medicine, 2022, , .	2.2	6
377	Utility of hematological and inflammatory biomarkers in predicting recovery in critical Covid-19 patients: Our experience in the largest Covid-19 treating center in Lebanon. PLoS ONE, 2022, 17, e0271393.	2.5	0

#	ARTICLE	IF	CITATIONS
378	Autophagy in health and disease: From molecular mechanisms to therapeutic target. MedComm, 2022, 3, .	7.2	30
379	The Relationship Between Pediatric Gut Microbiota and SARS-CoV-2 Infection. Frontiers in Cellular and Infection Microbiology, 0, 12, .	3.9	29
380	Role of Traditional Chinese Medicine in Treating Severe or Critical COVID-19: A Systematic Review of Randomized Controlled Trials and Observational Studies. Frontiers in Pharmacology, 0, 13, .	3.5	7
382	Paxlovid in patients who are immunocompromised and hospitalised with SARS-CoV-2 infection. Lancet Infectious Diseases, The, 2022, 22, 1279.	9.1	41
383	Co-Administration of Remdesivir and Azithromycin May Protect against Intensive Care Unit Admission in COVID-19 Pneumonia Requiring Hospitalization: A Real-Life Observational Study. Antibiotics, 2022, 11, 941.	3.7	4
384	Self-reported side effects of the Oxford AstraZeneca COVID-19 vaccine among healthcare workers in Ethiopia, Africa: A cross-sectional study. Frontiers in Public Health, 0, 10, .	2.7	12
385	Association between tocilizumab, sarilumab and all-cause mortality at 28 days in hospitalised patients with COVID-19: A network meta-analysis. PLoS ONE, 2022, 17, e0270668.	2.5	16
386	A Retrospective Study of Dexamethasone, Remdesivir, and Baricitinib in Severe COVID-19. Canadian Journal of Infectious Diseases and Medical Microbiology, 2022, 2022, 1-8.	1.9	2
387	The hunt for drugs for mild COVID: scientists seek to treat those at lower risk. Nature, 0, , .	27.8	4
388	A Framework for the Development of Living Practice Guidelines in Health Care. Annals of Internal Medicine, 2022, 175, 1154-1160.	3.9	34
389	In-hospital mortality in SARS-CoV-2 stratified by the use of corticosteroid. Annals of Medicine and Surgery, 2022, 80, .	1.1	1
390	JAK inhibition as a new treatment strategy for patients with COVID-19. Biochemical Pharmacology, 2022, 202, 115162.	4.4	10
391	Synthesis, spectral characterization, crystal structure and computational investigation of 2-formyl-6-methoxy-3-carbethoxy quinoline as potential SARS-CoV inhibitor. Journal of Physics and Chemistry of Solids, 2022, 170, 110886.	4.0	1
392	Systematic review and meta-analysis of ivermectin for treatment of COVID-19: evidence beyond the hype. BMC Infectious Diseases, 2022, 22, .	2.9	20
393	Answering Ireland's call: pathology during the COVID-19 pandemic. Journal of Clinical Pathology, 2022, 75, 721-723.	2.0	0
394	Efficacy and safety of vitamin D supplementation in hospitalized COVID-19 pediatric patients: A randomized controlled trial. Frontiers in Pediatrics, 0, 10, .	1.9	13
395	Origin, virological features, immune evasion and intervention of SARS-CoV-2 Omicron sublineages. Signal Transduction and Targeted Therapy, 2022, 7, .	17.1	96
396	Definitions matter: Heterogeneity of COVID-19 disease severity criteria and incomplete reporting compromise meta-analysis. PLOS Global Public Health, 2022, 2, e0000561.	1.6	10

#	ARTICLE	IF	CITATIONS
397	Critical patients COVID-19 has changed the management and outcomes in the ICU after 1 year of the pandemic? A multicenter, prospective, observational study. Enfermedades Infecciosas Y Microbiología Clínica (English Ed ), 2022, , .	0.3	0
398	Long-term functioning status of COVID-19 survivors: a prospective observational evaluation of a cohort of patients surviving hospitalisation. BMJ Open, 2022, 12, e057246.	1.9	12
399	Autoimmunity, cancer and COVID-19 abnormally activate wound healing pathways: critical role of inflammation. Histochemistry and Cell Biology, 2022, 158, 415-434.	1.7	8
400	COVID-19 as Another Trigger for HBV Reactivation: Clinical Case and Review of Literature. Pathogens, 2022, 11, 816.	2.8	13
401	Efficacy of Covexir® (<i>Ferula foetida</i> oleo-gum) treatment in symptomatic improvement of patients with mild to moderate COVID-19: A randomized, double-blind, placebo-controlled trial. Phytotherapy Research, 2022, 36, 4504-4515.	5.8	6
402	Assessing the proportion of the Danish population at risk of clinically significant drug-drug interactions with new oral antivirals for early treatment of COVID-19. International Journal of Infectious Diseases, 2022, 122, 599-601.	3.3	8
403	COVID-19 and Adult Acute Leukemia: Our Knowledge in Progress. Cancers, 2022, 14, 3711.	3.7	6
404	Institutional, therapeutic, and individual factors associated with 30-day mortality after COVID-19 diagnosis in Canadian long-term care facilities. Journal of the American Geriatrics Society, 2022, 70, 3210-3220.	2.6	7
405	Applying Lessons Learned From COVID-19 Therapeutic Trials to Improve Future ALI/ARDS Trials. Open Forum Infectious Diseases, 2022, 9, .	0.9	6
406	Tenofovir Disoproxil Fumarate/Emtricitabine and Baricitinib for Patients at High Risk of Severe Coronavirus Disease 2019: The PANCOVID Randomized Clinical Trial. Clinical Infectious Diseases, 2023, 76, e116-e125.	5.8	13
407	Antiviral drug treatment for nonsevere COVID-19: a systematic review and network meta-analysis. Cmaj, 2022, 194, E969-E980.	2.0	37
410	Real-world effectiveness of early remdesivir and sotrovimab in the highest-risk COVID-19 outpatients during the Omicron surge. Journal of Antimicrobial Chemotherapy, 2022, 77, 2693-2700.	3.0	41
411	Innate immune responses to three doses of the BNT162b2 mRNA SARS-CoV-2 vaccine. Frontiers in Immunology, 0, 13, .	4.8	13
412	Persistent T-cell exhaustion in relation to prolonged pulmonary pathology and death after severe COVID-19: Results from two Norwegian cohort studies. Journal of Internal Medicine, 2022, 292, 816-828.	6.0	4
413	COVID-19 pandemic: A multidisciplinary perspective on the pathogenesis of a novel coronavirus from infection, immunity and pathological responses. Frontiers in Immunology, 0, 13, .	4.8	3
414	Comparative risk assessment of COVID-19 associated mucormycosis and aspergillosis: A systematic review. Health Science Reports, 2022, 5, .	1.5	3
415	Estimating incidence of venous thromboembolism in COVID-19: Methodological considerations. Research and Practice in Thrombosis and Haemostasis, 2022, 6, .	2.3	3
416	Time to Stop Using Ineffective Covid-19 Drugs. New England Journal of Medicine, 2022, 387, 654-655.	27.0	18



#	ARTICLE	IF	CITATIONS
417	High Risk of Secondary Infections Following Thrombotic Complications in Patients With COVID-19. Open Forum Infectious Diseases, 2022, 9, .	0.9	1
418	Identification of CKD, bedridden history and cancer as higher-risk comorbidities and their impact on prognosis of hospitalized Omicron patients: a multi-centre cohort study. Emerging Microbes and Infections, 2022, 11, 2501-2509.	6.5	9
419	Mortality predictors in a cohort of patients with COVID-19 admitted to a large tertiary hospital in the city of S�o Paulo, Brazil: a retrospective study. Sao Paulo Medical Journal, 0, , .	0.9	0
420	A UPLC-MS/MS Method for Plasma Biological Monitoring of Nirmatrelvir and Ritonavir in the Context of SARS-CoV-2 Infection and Application to a Case. Journal of the American Society for Mass Spectrometry, 2022, 33, 1975-1981.	2.8	7
421	Lung-function trajectories in COVID-19 survivors after discharge: A two-year longitudinal cohort study. EClinicalMedicine, 2022, 54, 101668.	7.1	25
422	COVID-19 vaccine acceptance and its determinants among Vietnamese teachers: a web-based cross-sectional survey. AIMS Public Health, 2022, 9, 606-617.	2.6	2
423	Unfolding issues of immunity against SARS-CoV-2. Journal of Family Medicine and Primary Care, 2022, 11, 4878.	0.9	0
424	Wie hat das Coronavirus unsere sichere Welt der Selbstverst�ndlichkeiten ver�ndert?. , 2022, , 193-220.		0
425	Cost-effectiveness of remdesivir plus usual care versus usual care alone for hospitalized patients with COVID-19: an economic evaluation as part of the Canadian Treatments for COVID-19 (CATCO) randomized clinical trial. CMAJ Open, 2022, 10, E807-E817.	2.4	2
426	Perspective: repurposed Drugs for COVID-19. Archives of Medical Science, 2022, 18, 1378-1391.	0.9	3
427	Fluvoxamine for the treatment of COVID-19. The Cochrane Library, 2022, 2022, .	2.8	4
428	Coronavirus disease 2019 subphenotypes and differential treatment response to convalescent plasma in critically ill adults: secondary analyses of a randomized clinical trial. Intensive Care Medicine, 2022, 48, 1525-1538.	8.2	13
429	Evaluation of the Quality of COVID-19 Guidance Documents in Anaesthesia using the Appraisal of Guidelines for Research & Evaluation II (AGREE II) Instrument. British Journal of Anaesthesia, 2022, , .	3.4	0
430	A practical update on the management of patients with COVID��19. Clinical Medicine, 2022, 22, 468-474.	1.9	2
431	Saving millions of lives but some resources squandered: emerging lessons from health research system pandemic achievements and challenges. Health Research Policy and Systems, 2022, 20, .	2.8	5
432	Central Retinal Vein Occlusion After Discontinuation of Rivaroxaban Therapy in a Young Patient with COVID-19 Pulmonary Embolism: A Case Report. American Journal of Case Reports, 0, 23, .	0.8	1
433	AMMI Canada Practice Point: Treatments for adults with COVID-19 in 2021��2022. Jammi, 2022, 7, 163-169.	0.5	0
434	COVID-19 Therapies for inpatients: a review and quality assessment of clinical guidelines. ERJ Open Research, 0, , 00236-2022.	2.6	2

#	ARTICLE	IF	CITATIONS
435	Scars of COVID-19: A bibliometric analysis of post-COVID-19 fibrosis. <i>Frontiers in Public Health</i> , 0, 10, .	2.7	6
436	Efficacy and safety of chinese herbal medicine for treating mild or moderate COVID-19: A systematic review and meta-analysis of randomized controlled trials and observational studies. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	2
437	Nirmatrelvir combined with ritonavir for preventing and treating COVID-19. <i>The Cochrane Library</i> , 2022, 2022, .	2.8	23
438	Development of an In Vitro Model of SARS-CoV-Induced Acute Lung Injury for Studying New Therapeutic Approaches. <i>Antioxidants</i> , 2022, 11, 1910.	5.1	4
439	Network pharmacology and computer-aided drug design to explored potential targets of Lianhua Qingwen and Qingfei Paidu decoction for COVID-19. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	3
440	Guidelines for the prevention and management of children and adolescents with COVID-19. <i>European Journal of Pediatrics</i> , 2022, 181, 4019-4037.	2.7	10
441	Three out of four published systematic reviews on COVID-19 treatments were not registered and one-third of those registered were published: a meta-research study. <i>Journal of Clinical Epidemiology</i> , 2022, 152, 36-46.	5.0	7
443	Drug genetic associations with COVID-19 manifestations: a data mining and network biology approach. <i>Pharmacogenomics Journal</i> , 2022, 22, 294-302.	2.0	2
444	Ivermectin: A Controversial Focal Point during the COVID-19 Pandemic. <i>Life</i> , 2022, 12, 1384.	2.4	6
445	Feasibility of a telephone-delivered educational intervention for knowledge transfer of COVID-19-related information to older adults in Hong Kong: a pre-post-pilot study. <i>Pilot and Feasibility Studies</i> , 2022, 8, .	1.2	0
446	Personal reflective practice can lead to change. <i>BMJ, The</i> , 0, , o2394.	6.0	0
447	Consistency of covid-19 trial preprints with published reports and impact for decision making: retrospective review. , 2022, 1, e000309.		19
448	Glucocorticoid Therapy in Respiratory Illness: Bench to Bedside. <i>Journal of Investigative Medicine</i> , 2022, 70, 1662-1680.	1.6	2
449	Predictors of clinical evolution of SARS-CoV-2 infection in hematological patients: A systematic review and meta-analysis. <i>Hematological Oncology</i> , 2023, 41, 16-25.	1.7	6
450	Nitric Oxide and its Derivatives Containing Nasal Spray and Inhalation Therapy for the Treatment of COVID-19. <i>Current Pharmaceutical Design</i> , 2022, 28, 3658-3670.	1.9	3
451	Heterogenous treatment effects of dexamethasone 12 mg vs. 6 mg in patients with COVID-19 and severe hypoxaemia - post hoc exploratory analyses of the COVID STEROID 2 trial. <i>Acta Anaesthesiologica Scandinavica</i> , 0, , .	1.6	5
452	Efficacy and safety of baricitinib and tocilizumab in hospitalized patients with COVID-19: A comparison using systematic review and meta-analysis. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	7
453	Nirmatrelvir/Ritonavir and Molnupiravir in the Treatment of Mild/Moderate COVID-19: Results of a Real-Life Study. <i>Vaccines</i> , 2022, 10, 1731.	4.4	41



#	ARTICLE	IF	CITATIONS
454	Global Challenges with Oral Antivirals for COVID-19. Population Health Management, 2022, 25, 822-827.	1.7	1
456	Implications of an HbA1c-based Diabetes Screening on Prevalence and Effect of Dysglycemia in Patients With COVID-19. Journal of Clinical Endocrinology and Metabolism, 0, , .	3.6	1
458	Immune Modulation in Sepsis, ARDS, and Covid-19 “ The Road Traveled and the Road Ahead. , 2022, 1, .		6
459	Estimates of SARS-CoV-2 Omicron BA.2 Subvariant Severity in New England. JAMA Network Open, 2022, 5, e2238354.	5.9	43
460	Past, present and future of living systematic review: a bibliometrics analysis. BMJ Global Health, 2022, 7, e009378.	4.7	8
461	A randomised trial of anti-GM-CSF otilimab in severe COVID-19 pneumonia (OSCAR). European Respiratory Journal, 2023, 61, 2101870.	6.7	22
463	How pragmatic are randomized trials of remdesivir and favipiravir for in-hospital treatment of COVID-19: a descriptive methodological review of trial design using the PRECIS-2 framework. Journal of Clinical Epidemiology, 2022, 152, 193-200.	5.0	1
465	Glucocorticoids and COVID-19. Pharmacological Research, 2022, 185, 106511.	7.1	11
466	Real-Time Whole Genome Sequencing to Guide Patient-Tailored Therapy of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Clinical Infectious Diseases, 2023, 76, 1125-1128.	5.8	7
467	B-cell malignancies and COVID-19: a narrative review. Clinical Microbiology and Infection, 2023, 29, 332-337.	6.0	7
468	Association between prehospital medication and fatal outcomes in a cohort of hospitalized patients due to coronavirus disease-2019 in a referral hospital in Peru. Travel Medicine and Infectious Disease, 2022, 50, 102472.	3.0	1
469	Prolonged higher dose methylprednisolone<i>versus</i>conventional dexamethasone in COVID-19 pneumonia: a randomised controlled trial (MEDEAS). European Respiratory Journal, 2023, 61, 2201514.	6.7	18
470	Effective knowledge mobilisation: creating environments for quick generation, dissemination, and use of evidence. BMJ, The, 0, , e070195.	6.0	1
472	Randomized Open Investigation Determining Steroid Dose in Severe COVID-19: The ROIDS-Dose Clinical Trial. Cureus, 2022, , .	0.5	1
473	Comparative effectiveness of sotrovimab and molnupiravir for prevention of severe covid-19 outcomes in patients in the community: observational cohort study with the OpenSAFELY platform. BMJ, The, 0, , e071932.	6.0	42
474	Oral Antiviral Treatment for COVID-19: A Comprehensive Review on Nirmatrelvir/Ritonavir. Viruses, 2022, 14, 2540.	3.3	33
475	Early administration of tofacitinib in <sc>COVID</sc>“19 pneumonitis: An open randomised controlled trial. European Journal of Clinical Investigation, 2023, 53, .	3.4	3
476	Pathophysiological mechanisms of thrombosis in acute and long COVID-19. Frontiers in Immunology, 0, 13, .	4.8	24

#	ARTICLE	IF	CITATIONS
477	WHO Living Guidelines on antivirals for COVID-19 are evidence-based. Lancet, The, 2022, 400, 2196-2198.	13.7	6
478	Ivermectin role in the prevention of COVID-19: A systematic review and meta-analysis. Journal of Clinical Pharmacology, 0, , .	2.0	1
479	Antibody tests for identification of current and past infection with SARS-CoV-2. The Cochrane Library, 2022, 2022, .	2.8	32
480	Effects of Different Corticosteroid Doses in Elderly Unvaccinated Patients with Severe to Critical COVID-19. Life, 2022, 12, 1924.	2.4	1
481	Covid-19: "Grotesque inequity" that only a quarter of paxlovid courses go to poorer countries. BMJ, The, 0, , o2795.	6.0	3
482	Glycyrrhizic acid alters the hyperoxidative stress-induced differentiation commitment of MSCs by activating the Wnt/ $\beta$ 2-catenin pathway to prevent SONFH. Food and Function, 2023, 14, 946-960.	4.6	9
483	A case of amebic colitis and liver abscesses that occurred after treatment of coronavirus disease 2019 with dexamethasone. IDCases, 2023, 31, e01648.	0.9	1
484	Directions of development of functional missions of computer pharmaceutical knowledge bases taking into account various types of crisis situations. Farmatsevtichnyi Zhurnal, 2022, , 47-56.	0.4	1
485	Antiviral Activity of Interferon alfa-2b and Taurine Combination Against SARS-CoV-2 &lt;i>in vitro&lt;/i>. Antibiotiki i Khimioterapiya, 0, , .	0.6	0
486	Honey and <sc><i>Nigella sativa</i></sc> against <sc>COVID</sc>-19 in Pakistan (<sc>HNS&lt;sc>COVID&lt;sc>PK</sc>): A multicenter placebo-controlled randomized clinical trial. Phytotherapy Research, 2023, 37, 627-644.	5.8	20
487	Corticosteroid treatment in severe patients with SARS-CoV-2 and chronic HBV co-infection: a retrospective multicenter study. BMC Infectious Diseases, 2022, 22, .	2.9	2
488	How Protective are Antibodies to SARS-CoV-2, the Main Weapon of the B-Cell Response?. Stem Cell Reviews and Reports, 0, , .	3.8	2
489	The Association of Low CD4 Expression on Monocytes and Low CD8+ T-Cell Count at Hospital Admission Predicts the Need for Mechanical Ventilation in Patients With COVID-19 Pneumonia: A Prospective Monocentric Cohort Study. , 2022, 4, e0810.		2
490	Lessons From a Negative Clinical Trial: Novel Immunological Targets for COVID-19 and Beyond*. Critical Care Medicine, 2023, 51, 153-156.	0.9	0
491	Risk of Malnutrition in Hospitalized COVID-19 Patients: A Systematic Review and Meta-Analysis. Nutrients, 2022, 14, 5267.	4.1	7
492	Ruxolitinib for severe fever with thrombocytopenia syndrome (SFTS). Heliyon, 2022, 8, e12462.	3.2	0
493	Supervised Machine Learning Models to Identify Early-Stage Symptoms of SARS-CoV-2. Sensors, 2023, 23, 40.	3.8	9
494	Respiratory Viruses and Cystic Fibrosis. Seminars in Respiratory and Critical Care Medicine, 2023, 44, 196-208.	2.1	1

#	ARTICLE	IF	CITATIONS
495	Clinical Outcomes and Survival Analysis of Remdesivir as a Treatment Option for Moderate to Severe COVID-19 Patients. Covid, 2022, 2, 1758-1767.	1.5	0
496	SARS-CoV-2 induces “cytokine storm” hyperinflammatory responses in RA patients through pyroptosis. Frontiers in Immunology, 0, 13, .	4.8	8
497	Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial. Lancet, The, 2023, 401, 281-293.	13.7	174
498	Regional trends in the use of steroids and favipiravir for COVID-19 treatment. Journal of Infection and Public Health, 2022, , .	4.1	0
499	Sequential Treatment by Antiviral Drugs Followed by Immunosuppressive Agents for COVID-19 Patients with Hematological Malignancy. Infection and Drug Resistance, 0, Volume 15, 7117-7124.	2.7	1
500	Drug-induced liver injury following the use of tocilizumab or sarilumab in patients with coronavirus disease 2019. BMC Infectious Diseases, 2022, 22, .	2.9	3
502	Validation of a specialized evaluation system for COVID-19 in Japan: A retrospective, multicenter cohort study. Journal of Infection and Chemotherapy, 2022, , .	1.7	0
503	Influenza antivirals and their role in pandemic preparedness. Antiviral Research, 2023, 210, 105499.	4.1	17
504	The “myth of Hydroxychloroquine (HCQ) as post-exposure prophylaxis (PEP) for the prevention of COVID-19” is far from reality. Scientific Reports, 2023, 13, .	3.3	3
505	Evaluation of urinary cysteinyl leukotrienes as biomarkers of severity and putative therapeutic targets in COVID-19 patients. Inflammation Research, 0, , .	4.0	2
506	A Review of Coronavirus Disease 2019 in Pregnancy. Seminars in Respiratory and Critical Care Medicine, 2023, 44, 050-065.	2.1	0
507	Multicenter Case“Control Study of COVID-19”Associated Mucormycosis Outbreak, India. Emerging Infectious Diseases, 2023, 29, 8-19.	4.3	33
508	Trends, variation, and clinical characteristics of recipients of antiviral drugs and neutralising monoclonal antibodies for covid-19 in community settings: retrospective, descriptive cohort study of 23.4 million people in OpenSAFELY. , 2023, 2, e000276.		10
509	Clinical characteristics and clinical outcome of community clusters with SARS-CoV-2 infection. Frontiers in Public Health, 0, 10, .	2.7	0
510	The evidence base for emergency use authorizations for COVID-19 treatments: A rapid review. Health Science Reports, 2023, 6, .	1.5	1
511	Polypharmacology of ambroxol in the treatment of COVID-19. Bioscience Reports, 0, , .	2.4	0
512	Methods for living guidelines: early guidance based on practical experience. Paper 1: Introduction. Journal of Clinical Epidemiology, 2023, 155, 84-96.	5.0	17
513	A mixed methods study exploring requests for unproven COVID therapies such as ivermectin and healthcare distrust in the rural South. Preventive Medicine Reports, 2023, 31, 102104.	1.8	0

#	ARTICLE	IF	CITATIONS
514	Time to negative PCR conversion amongst high-risk patients with mild-to-moderate Omicron BA.1 and BA.2 COVID-19 treated with sotrovimab or nirmatrelvir. <i>Clinical Microbiology and Infection</i> , 2023, 29, 543.e5-543.e9.	6.0	9
516	Early Treatment with Monoclonal Antibodies or Convalescent Plasma Reduces Mortality in Non-Vaccinated COVID-19 High-Risk Patients. <i>Viruses</i> , 2023, 15, 119.	3.3	6
518	WV116 versus Nirmatrelvir/Ritonavir for Oral Treatment of Covid-19. <i>New England Journal of Medicine</i> , 2023, 388, 406-417.	27.0	97
520	Exploring the Role of Immune System and Inflammatory Cytokines in SARS-CoV-2 Induced Lung Disease: A Narrative Review. <i>Biology</i> , 2023, 12, 177.	2.8	11
521	Sepsis presentation and pathophysiology. , 2023, , 489-501.		0
523	Use of Monoclonal Antibodies in Immunocompromised Patients Hospitalized with Severe COVID-19: A Retrospective Multicenter Cohort. <i>Journal of Clinical Medicine</i> , 2023, 12, 864.	2.4	4
524	Nirmatrelvir/Ritonavir therapy and COVID-19 vaccination improve clinical outcomes of SARS-CoV-2 Omicron variant infection. <i>Journal of Medical Virology</i> , 2023, 95, .	5.0	5
526	Effects of the COVID-19 Pandemic on Patients With NMO Spectrum Disorders and MOG-Antibody-Associated Diseases. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2023, 10, .	6.0	7
527	Treatment of patients with pericarditis with anti-inflammatory drugs. <i>Klinicheskaia Meditsina</i> , 2023, 100, 509-519.	0.1	2
528	The Research Progress of COVID-19 Related Kidney Injury. <i>Advances in Clinical Medicine</i> , 2023, 13, 1452-1460.	0.0	0
529	The D405N Mutation in the Spike Protein of SARS-CoV-2 Omicron BA.5 Inhibits Spike/Integrins Interaction and Viral Infection of Human Lung Microvascular Endothelial Cells. <i>Viruses</i> , 2023, 15, 332.	3.3	5
530	Association between ivermectin treatment and mortality in COVID-19: A hospital-based case-control study. <i>Journal of Family Medicine and Primary Care</i> , 2023, 12, 139.	0.9	0
531	The Role of Steroids. <i>Lessons From the ICU</i> , 2023, , 265-276.	0.1	0
532	Identification of structural scaffold from interbioscreen (IBS) database to inhibit 3CLpro, PLpro, and RdRp of SARS-CoV-2 using molecular docking and dynamic simulation studies. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 13168-13179.	3.5	0
533	A lingua franca for guidelines or a Tower of Babel?. <i>Acta Anaesthesiologica Scandinavica</i> , 2023, 67, 840-841.	1.6	1
534	Neutralization of the new coronavirus by extracting their spikes using engineered liposomes. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2023, 50, 102674.	3.3	2
535	Insights from comparison of the clinical presentation and outcomes of patients hospitalized with COVID-19 in an Italian internal medicine ward during first and third wave. <i>Frontiers in Medicine</i> , 0, 10, .	2.6	3
536	Conceptualizing the reporting of living systematic reviews. <i>Journal of Clinical Epidemiology</i> , 2023, 156, 113-118.	5.0	1

#	ARTICLE	IF	CITATIONS
537	Host immunological responses facilitate development of SARS-CoV-2 mutations in patients receiving monoclonal antibody treatments. <i>Journal of Clinical Investigation</i> , 2023, 133, .	8.2	16
539	Use of COVID-19 Convalescent Plasma for Treatment of Symptomatic SARS-CoV-2 Infection at a Children's Hospital: A Contribution to a Still Inadequate Body of Evidence. <i>Children</i> , 2023, 10, 350.	1.5	1
540	Use and effectiveness of remdesivir for the treatment of patients with covid-19 using data from the Lean European Open Survey on SARS-CoV-2 infected patients (LEOSS): a multicentre cohort study. <i>Infection</i> , 2023, 51, 1033-1049.	4.7	8
541	Quercetin for the treatment of COVID-19 patients: A systematic review and meta-analysis. <i>Reviews in Medical Virology</i> , 2023, 33, .	8.3	12
542	Compliance with World Health Organization's COVID-19 guidelines among Iraqi health workers. <i>World Medical and Health Policy</i> , 0, , .	1.6	0
543	Insights into COVID-19-associated critical illness: a narrative review. <i>Annals of Translational Medicine</i> , 2023, 11, 220-220.	1.7	2
544	French pharmacovigilance survey of casirivimab - imdevimab monoclonal antibodies in coronavirus disease (COVID-19). <i>Therapie</i> , 2023, , .	1.0	0
545	Molnupiravir and nirmatrelvir-ritonavir reduce mortality risk during post-acute COVID-19 phase. <i>Journal of Infection</i> , 2023, , .	3.3	3
546	Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials. <i>Lancet Respiratory Medicine</i> , the, 2023, 11, 453-464.	10.7	35
547	Could the fibromyalgia syndrome be triggered or enhanced by COVID-19?. <i>Inflammopharmacology</i> , 2023, 31, 633-651.	3.9	9
548	Pituitary and SARS CoV-2: An unremitting conundrum. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2023, 37, 101752.	4.7	6
549	CFTR Inhibitors Display In Vitro Antiviral Activity against SARS-CoV-2. <i>Cells</i> , 2023, 12, 776.	4.1	3
550	Low vitamin D levels predict outcomes of COVID-19 in patients with both severe and non-severe disease at hospitalization. <i>Endocrine</i> , 2023, 80, 669-683.	2.3	13
551	Effects of 12Âmg vs. 6Âmg dexamethasone on thromboembolism and bleeding in patients with critical COVID-19 - a post hoc analysis of the randomized, blinded COVID STEROID 2 trial. <i>Annals of Intensive Care</i> , 2023, 13, .	4.6	1
552	Outcome of COVID-19 patients with haematological malignancies after the introduction of vaccination and monoclonal antibodies: results from the HM-COV 2.0 study. <i>Clinical and Experimental Medicine</i> , 2023, 23, 2275-2285.	3.6	1
553	A patient-tailored approach for corticosteroid treatment in COVID-19: still not there yet. <i>European Respiratory Journal</i> , 2023, 61, 2300270.	6.7	0
554	GRADE guidance 36: updates to GRADE's approach to addressing inconsistency. <i>Journal of Clinical Epidemiology</i> , 2023, 158, 70-83.	5.0	15
555	Case Series of Patients with Coronavirus Disease 2019 Pneumonia Treated with Hydroxychloroquine. <i>Medicina (Lithuania)</i> , 2023, 59, 541.	2.0	1

#	ARTICLE	IF	CITATIONS
556	Perspective from anesthesiologists on the therapy of critically ill patients with COVID-19. , 2023, 1, .		1
557	Colchicine reduces the activation of NLRP3 inflammasome in COVID-19 patients. Inflammation Research, 2023, 72, 895-899.	4.0	2
558	Steroid Pulse Therapy as a Treatment for Patients With COVID-19 Pneumonia at an Intensive Care Unit: A Single-Center Retrospective Observational Study. Cureus, 2023, , .	0.5	0
559	Identification of berberine as a potential therapeutic strategy for kidney clear cell carcinoma and COVID-19 based on analysis of large-scale datasets. Frontiers in Immunology, 0, 14, .	4.8	1
560	Changing patterns and clinical outcomes of hospitalized patients with COVID-19 severe pneumonia treated with remdesivir according to vaccination status: results from a real-world retrospective study. Clinical and Experimental Medicine, 2023, 23, 2749-2756.	3.6	5
561	Remdesivir for COVID-19 and acute kidney injury: disproportionality analysis of data from the U.S. Food and Drug Administration Adverse Event Reporting System. International Journal of Clinical Pharmacy, 2023, 45, 509-514.	2.1	6
562	Clinical application of SARS-CoV-2 antibody detection and monoclonal antibody therapies against COVID-19. World Journal of Clinical Cases, 0, 11, 2168-2180.	0.8	2
563	Hyperinflammation and complement in COVID-19. American Journal of Hematology, 2023, 98, .	4.1	10
564	Did Ghana Do Enough? A Scientometric Analysis of COVID-19 Research Output from Ghana within the African Context. Diseases (Basel, Switzerland), 2023, 11, 56.	2.5	1
565	Host-Based Treatments for Severe COVID-19. Current Issues in Molecular Biology, 2023, 45, 3102-3121.	2.4	3
566	Data-driven analysis to understand long COVID using electronic health records from the RECOVER initiative. Nature Communications, 2023, 14, .	12.8	12
567	Use of Remdesivir in Patients with SARS-CoV-2 Pneumonia in a Real-Life Setting during the Second and Third COVID-19 Epidemic Waves. Viruses, 2023, 15, 947.	3.3	2
568	Antiviral Activity of Acetylsalicylic Acid against Bunyamwera Virus in Cell Culture. Viruses, 2023, 15, 948.	3.3	0
569	Investigational Use of Mesenchymal Stem/Stromal Cells and Their Secretome as Add-On Therapy in Severe Respiratory Virus Infections: Challenges and Perspectives. Advances in Therapy, 2023, 40, 2626-2692.	2.9	8
571	Meta-Analysis of Glucocorticoids for Covid-19 Patients Not Receiving Oxygen. , 2023, 2, .		7
572	Therapeutic strategies for COVID-19: progress and lessons learned. Nature Reviews Drug Discovery, 2023, 22, 449-475.	46.4	112
573	Effect of remdesivir post-exposure prophylaxis and treatment on pathogenesis of measles in rhesus macaques. Scientific Reports, 2023, 13, .	3.3	2
574	Causal Bayesian machine learning to assess treatment effect heterogeneity by dexamethasone dose for patients with COVID-19 and severe hypoxemia. Scientific Reports, 2023, 13, .	3.3	4



#	ARTICLE	IF	CITATIONS
575	Clinical progression, disease severity, and mortality among adults hospitalized with COVID-19 caused by the Omicron and Delta SARS-CoV-2 variants: A population-based, matched cohort study. PLoS ONE, 2023, 18, e0282806.	2.5	10
576	Efficacy of Tocilizumab in Severely Ill COVID-19 Patients With Rapid Respiratory Deterioration: A Single Center Experience During the Third Pandemic Wave in Greece. In Vivo, 2023, 37, 1312-1317.	1.3	0
578	Efficiency of Levilimab in patients with moderate and severe COVID-19. Farmakoekonomika, 2023, 16, 36-47.	1.2	0
579	Unveiling the Unexpected: Why Doctors Should Look beyond the Lungs when Predicting COVID-19 Mortality. Kidney and Blood Pressure Research, 2023, 48, 347-356.	2.0	0
580	Optimal Dosing and Timing of High-Dose Corticosteroid Therapy in Hospitalized Patients With COVID-19: Study Protocol for a Retrospective Observational Multicenter Study (SELECT). JMIR Research Protocols, 0, 12, e48183.	1.0	1
581	Therapeutics for COVID-19. Nature Microbiology, 2023, 8, 771-786.	13.3	28
582	Corticosteroids in ARDS. Journal of Clinical Medicine, 2023, 12, 3340.	2.4	4
583	Nirmatrelvir/Ritonavir for hemodialysis patients with COVID-19. Frontiers in Pharmacology, 0, 14, .	3.5	1
584	Two Years of Experience and Methodology of Korean COVID-19 Living Clinical Practice Guideline Development. Journal of Korean Medical Science, 2023, 38, .	2.5	0
585	Controlled human infection models in COVID-19 and tuberculosis: current progress and future challenges. Frontiers in Immunology, 0, 14, .	4.8	1
586	Heart Failure Management in 2023: A Pharmacotherapy- and Lifestyle-Focused Comparison of Current International Guidelines. CJC Open, 2023, 5, 629-640.	1.5	2
588	Î2-Cyclodextrins as affordable antivirals to treat coronavirus infection. Biomedicine and Pharmacotherapy, 2023, 164, 114997.	5.6	3
589	Efficacy and safety of interleukin-6 receptor antagonists in adult patients admitted to intensive care unit with COVID-19: A systematic review and meta-analysis of randomized controlled trials. Preventive Medicine Reports, 2023, 34, 102276.	1.8	0
590	Dicoumarol is an effective post-exposure prophylactic for SARS-CoV-2 Omicron infection in human airway epithelium. Signal Transduction and Targeted Therapy, 2023, 8, .	17.1	0
591	Glucocorticoid-induced activation of NOX/ROS/NF-ÎB signaling in MSCs contributes to the development of GONFH. Apoptosis: an International Journal on Programmed Cell Death, 0, , .	4.9	1
592	Pharmacological approaches to pulmonary fibrosis following COVID-19. Frontiers in Pharmacology, 0, 14, .	3.5	3
593	Caring for Patients With Acute Respiratory Distress Syndrome. JAMA - Journal of the American Medical Association, 2023, 330, 368.	7.4	6
594	Targeting SARS-CoV-2 Main Protease (MPro) with Kinase Inhibitors: A Promising Approach for Discovering Antiviral and Anti-inflammatory Molecules against SARS-CoV-2. Journal of Chemical Information and Modeling, 2023, 63, 4138-4146.	5.4	1

#	ARTICLE	IF	CITATIONS
595	Treatment of COVID-19 during the Acute Phase in Hospitalized Patients Decreases Post-Acute Sequelae of COVID-19. <i>Journal of Clinical Medicine</i> , 2023, 12, 4158.	2.4	3
596	How to recognize a trustworthy clinical practice guideline. <i>Journal of Anesthesia, Analgesia and Critical Care</i> , 2023, 3, .	1.3	1
597	Efficacy and safety of molnupiravir in adult outpatients with COVID-19. <i>AlĖmanah KliniĖskoj Mediciny</i> , 2023, 51, 86-98.	0.3	1
598	COVID-19 and Pregnancy: An Updated Review about Evidence-Based Therapeutic Strategies. <i>Journal of Personalized Medicine</i> , 2023, 13, 1035.	2.5	1
599	Theory and Practice of Glucocorticoids in COVID-19: Getting to the Heart of the MatterĖ”A Critical Review and Viewpoints. <i>Pharmaceuticals</i> , 2023, 16, 924.	3.8	1
600	Calibrating Oxygen Saturation Measurements for Different Skin Colors Using the Individual Typology Angle. <i>IEEE Sensors Journal</i> , 2023, 23, 16993-17001.	4.7	0
601	Serum TGFĖ $\beta$ 2 as a predictive biomarker for severe disease and fatality of COVIDĖ19. <i>European Journal of Immunology</i> , 2023, 53, .	2.9	1
602	Reducing uncertainty in evidenceĖbased health policy by integrating empirical and theoretical evidence: An EbM+theory approach. <i>Journal of Evaluation in Clinical Practice</i> , 2023, 29, 1279-1293.	1.8	1
603	Molnupiravir for the treatment of non-severe COVID-19: a systematic review and meta-analysis of 14 randomized trials with 34Ė570 patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2023, 78, 2131-2139.	3.0	4
604	Update of recommendations for the management of COVID-19 in patients with haematological malignancies, haematopoietic cell transplantation and CAR T therapy, from the 2022 European Conference on Infections in Leukaemia (ECIL 9). <i>Leukemia</i> , 2023, 37, 1933-1938.	7.2	4
605	Oral azvudine for mildĖtoĖmoderate COVIDĖ19 in high risk, nonhospitalized adults: Results of a realĖworld study. <i>Journal of Medical Virology</i> , 2023, 95, .	5.0	5
606	An Updated Systematic Review on RemdesivirĖ™s Safety and Efficacy in Patients Afflicted With COVID-19. <i>Cureus</i> , 2023, , .	0.5	0
607	AntibodyĖmediated rejection in xenotransplantation: Can it be prevented or reversed?. <i>Xenotransplantation</i> , 2023, 30, .	2.8	1
608	Dexamethasone attenuates interferon-related cytokine hyperresponsiveness in COVID-19 patients. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	6
609	Remdesivir: A Review in COVID-19. <i>Drugs</i> , 2023, 83, 1215-1237.	10.9	4
610	DeepGT: Deep learning-based quantification of nanosized bioparticles in bright-field micrographs of Cires-Tournois biosensor. <i>Nano Today</i> , 2023, 52, 101968.	11.9	1
611	Assessment of the available therapeutic approaches for severe COVID-19: a meta-analysis of randomized controlled trials. <i>Scientific Reports</i> , 2023, 13, .	3.3	1
612	COVID-19 and cardiovascular disease in patients with chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 0, , .	0.7	2



#	ARTICLE	IF	CITATIONS
613	COVID-19 in third trimester of pregnancy. Journal of Advanced Pharmaceutical Technology and Research, 2023, 14, 171.	1.0	1
614	Comparative effectiveness of sotrovimab and molnupiravir for preventing severe COVID-19 outcomes in patients on kidney replacement therapy: observational study using the OpenSAFELY-UKRR and SRR databases. CKJ: Clinical Kidney Journal, 2023, 16, 2048-2058.	2.9	2
615	Viral rebound and safety of nirmatrelvir/ritonavir for lung-transplant recipients infected with SARS-CoV-2. Biosafety and Health, 2023, 5, 266-271.	2.7	0
616	Traditional Herbal Medicines and Their Active Constituents in Combating SARS-CoV-2 Infection. , 2023, , 137-188.		0
618	Development of a Novel Clinical Risk Score for COVID-19 Infections. American Journal of Medicine, 2023, , .	1.5	0
619	Quality of reporting of adverse events in clinical trials of covid-19 drugs: systematic review. , 2023, 2, e000352.		1
621	Rapid Response to Remdesivir in Hospitalised COVID-19 Patients: A Propensity Score Weighted Multicentre Cohort Study. Infectious Diseases and Therapy, 2023, 12, 2471-2484.	4.0	0
622	ETIOTROPIC THERAPY OF MILD COVID-19 IN OUTPATIENT PATIENTS: MOLNUPIRAVIR IS IN FOCUS. Acta Medica Eurasica, 2023, , 1-15.	0.3	0
623	Effectiveness of nirmatrelvir-ritonavir for the treatment of patients with mild to moderate COVID-19 and at high risk of hospitalization: Systematic review and meta-analyses of observational studies. PLoS ONE, 2023, 18, e0284006.	2.5	1
624	Effect of swine glyco-humanized polyclonal neutralizing antibody on survival and respiratory failure in patients hospitalized with severe COVID-19: A Randomized, placebo-controlled Trial. Open Forum Infectious Diseases, 0, , .	0.9	0
625	Intravenous Vitamin C for Patients Hospitalized With COVID-19. JAMA - Journal of the American Medical Association, 2023, 330, 1745.	7.4	7
626	Effect of ursodeoxycholic acid on preventing SARS-CoV-2 infection in patients with liver transplantation: a multicenter retrospective cohort study. QJM - Monthly Journal of the Association of Physicians, 0, , .	0.5	2
627	Nirmatrelvir combined with ritonavir for preventing and treating COVID-19. The Cochrane Library, 2023, 2023, .	2.8	0
628	Early mobilisation in critically ill COVID-19 patients: a subanalysis of the ESICM-initiated UNITE-COVID observational study. Annals of Intensive Care, 2023, 13, .	4.6	0
629	Regional moderate hyperthermia for mild-to-moderate COVID-19 (TherMoCoV study): a randomized controlled trial. Frontiers in Medicine, 0, 10, .	2.6	0
630	Bacteremia with Multi-drug Resistant Gram-negative Bacteria in Pediatrics and Its Correlation with COVID-19. Archives of Clinical Infectious Diseases, 2023, 18, .	0.2	0
631	Clinical outcomes of mild to moderate coronavirus disease 2019 patients treated with Regdanvimab in delta-variant outbreak: Retrospective cohort study. Medicine (United States), 2023, 102, e35987.	1.0	1
632	Probiotics for the prevention and treatment of COVID-19: a rapid systematic review and meta-analysis. Frontiers in Nutrition, 0, 10, .	3.7	2

#	ARTICLE	IF	CITATIONS
633	Suppressed transcript diversity and immune response in COVID-19 ICU patients: a longitudinal study. Life Science Alliance, 2024, 7, e202302305.	2.8	0
634	Discovery of Anti-Coronavirus Cinnamoyl Triterpenoids Isolated from Hippophae rhamnoides during a Screening of Halophytes from the North Sea and Channel Coasts in Northern France. International Journal of Molecular Sciences, 2023, 24, 16617.	4.1	0
635	Effects of evidence-based clinical practice guidelines for COVID-19 in health care quality improvements. A third systematic review.. F1000Research, 0, 12, 1501.	1.6	0
636	Unveiling patenting strategies of therapeutics and vaccines: evergreening in the context of COVID-19 pandemic. Frontiers in Medicine, 0, 10, .	2.6	0
637	A multinational case series describing successful treatment of persistent SARS-CoV-2 infection caused by Omicron sublineages with prolonged courses of nirmatrelvir/ritonavir.. Open Forum Infectious Diseases, 0, , .	0.9	0
638	Global trends in research on endothelial cells and sepsis between 2002 and 2022: A systematic bibliometric analysis. Heliyon, 2024, 10, e23599.	3.2	0
640	The metaproteome of the gut microbiota in pediatric patients affected by COVID-19. Frontiers in Cellular and Infection Microbiology, 0, 13, .	3.9	0
642	Clinical features that predict the mortality risk in older patients with Omicron pneumonia: the MLWAP score. Internal and Emergency Medicine, 0, , .	2.0	0
643	Clinical course and management of COVID-19 in the era of widespread population immunity. Nature Reviews Microbiology, 2024, 22, 75-88.	28.6	1
644	Azvadine and nirmatrelvirâ€“ritonavir in hospitalized patients with moderateâ€“toâ€“severe COVIDâ€“19: Emulation of a randomized target trial. Journal of Medical Virology, 2023, 95, .	5.0	0
645	Implementation of Recommendations on the Use of Corticosteroids in Severe COVID-19. JAMA Network Open, 2023, 6, e2346502.	5.9	0
646	Serum Câ€“reactive protein greater than 75â€“mg/dL as an early available laboratory predictor of severe COVIDâ€“19: A systematic review. Immunity, Inflammation and Disease, 2023, 11, .	2.7	0
647	<i>Nigella sativa</i> for the treatment of COVIDâ€“19 patients: A rapid systematic review and metaâ€“analysis of randomized controlled trials. Food Science and Nutrition, 2024, 12, 2061-2067.	3.4	0
648	Agranulocytosis and secondary infection related to JAK inhibitors and IL-6 receptor blockers: a disproportionality analysis using the US Food and drug administration adverse event reporting system. Frontiers in Pharmacology, 0, 14, .	3.5	0
649	Barriers to and facilitators of living guidelines use in low-income and middle-income countries: a scoping review. BMJ Open, 2024, 14, e074311.	1.9	0
650	Tofacitinib in Patients Hospitalized With Moderate and Severe COVID-19: Not Just Another Kinase Inhibitor. Cureus, 2024, , .	0.5	0
651	Risk factors, outcomes, and epidemiological and etiological study of hospitalized COVID-19 patients with bacterial co-infection and secondary infections. European Journal of Clinical Microbiology and Infectious Diseases, 2024, 43, 577-586.	2.9	0
653	Effectiveness and safety of nirmatrelvir-ritonavir in kidney transplant recipients with severe kidney dysfunction infected with COVID-19. Antimicrobial Agents and Chemotherapy, 2024, 68, .	3.2	0

#	ARTICLE	IF	CITATIONS
654	Exploring nasopharyngeal microbiota profile in children affected by SARS-CoV-2 infection. Microbiology Spectrum, 2024, 12, .	3.0	0
655	Questionnaire survey of risk factors for recurrence of ocular inflammation in patients with uveitis after SARS-CoV-2 infection. Frontiers in Cellular and Infection Microbiology, 0, 13, .	3.9	0
656	The clinical application of traditional Chinese medicine NRICM101 in hospitalized patients with COVID-19. Expert Review of Anti-Infective Therapy, 0, , 1-9.	4.4	0
657	Anti-inflammatory Drugs: Glucocorticoids. , 2023, , 265-275.		0
658	Trustworthy evidence-based versus untrustworthy guidelines: detecting the difference. Family Medicine and Community Health, 2023, 11, e002437.	1.6	0
660	Structural insights into IL-6 signaling inhibition by therapeutic antibodies. Cell Reports, 2024, 43, 113819.	6.4	0
661	Effect of prone position in non-intubated COVID-19 patients. Pneumon, 2024, 37, 1-17.	0.3	0
662	Anti-synthetase syndrome is associated with a higher risk of hospitalization among patients with idiopathic inflammatory myopathy and COVID-19. Frontiers in Immunology, 0, 15, .	4.8	0
663	Impact of corticosteroids on initiation and half-year durability of humoral response in COVID-19 survivors. , 2024, 2, 48-55.		0
664	Ivermectin for treatment of COVID-19: A systematic review and meta-analysis. Heliyon, 2024, 10, e27647.	3.2	0